The report on the Thyroid Hormone Disorder Drug market provides a birds eye view of the current proceeding within the Thyroid Hormone Disorder Drug market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Thyroid Hormone Disorder Drug market and offers a clear assessment of the projected market fluctuations during the forecast period. The different factors that are likely to impact the overall dynamics of the Thyroid Hormone Disorder Drug market over the forecast period (2019-2029) including the current trends, growth opportunities, restraining factors, and more are discussed in detail in the market study.

The recent published research report sheds light on critical aspects of the global Thyroid Hormone Disorder Drug market such as vendor landscape, competitive strategies, market drivers and challenges along with the regional analysis. The report helps the readers to draw a suitable conclusion and clearly understand the current and future scenario and trends of global Thyroid Hormone Disorder Drug market. The research study comes out as a compilation of useful guidelines for players to understand and define their strategies more efficiently in order to keep themselves ahead of their competitors. The report profiles leading companies of the global Thyroid Hormone Disorder Drug market along with the emerging new ventures who are creating an impact on the global market with their latest innovations and technologies.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2551575&source=atm

The recent published study includes information on key segmentation of the global Thyroid Hormone Disorder Drug market on the basis of type/product, application and geography (country/region). Each of the segments included in the report is studies in relations to different factors such as market size, market share, value, growth rate and other quantitate information.

The competitive analysis included in the global Thyroid Hormone Disorder Drug market study allows their readers to understand the difference between players and how they are operating amounts themselves on global scale. The research study gives a deep insight on the current and future trends of the market along with the opportunities for the new players who are in process of entering global Thyroid Hormone Disorder Drug market. Market dynamic analysis such as market drivers, market restraints are explained thoroughly in the most detailed and easiest possible manner. The companies can also find several recommendations improve their business on the global scale.

The readers of the Thyroid Hormone Disorder Drug Market report can also extract several key insights such as market size of varies products and application along with their market share and growth rate. The report also includes information for next five years as forested data and past five years as historical data and the market share of the several key information.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2551575&source=atm

Global Thyroid Hormone Disorder Drug Market by Companies:

The company profile section of the report offers great insights such as market revenue and market share of global Thyroid Hormone Disorder Drug market. Key companies listed in the report are:

The following manufacturers are covered:Novo NordiskSanofiMerckEli LillyAstraZenecaAbbVie

Segment by RegionsNorth AmericaEuropeChinaJapanSoutheast AsiaIndia

Segment by TypeInjectionOralOthers

Segment by ApplicationHospitalClinicMedical CenterOthers

Global Thyroid Hormone Disorder Drug Market by Geography:

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2551575&licType=S&source=atm

Some of the Major Highlights of TOC covers in Thyroid Hormone Disorder Drug Market Report:

Chapter 1: Methodology & Scope of Thyroid Hormone Disorder Drug Market

Chapter 2: Executive Summary of Thyroid Hormone Disorder Drug Market

Chapter 3: Thyroid Hormone Disorder Drug Industry Insights

Chapter 4: Thyroid Hormone Disorder Drug Market, By Region

Chapter 5: Company Profile

And Continue

Read more:
The impact of the coronavirus on the Thyroid Hormone Disorder Drug Market Analysis Research and Trends Report for 2020-2029 3w Market News Reports -...

Recommendation and review posted by Bethany Smith

By: Taylor Roar, Capital News Service

Health professionals and federal agencies have expressed concern about the mental health effects of the global pandemic and social isolation. Mental health experts worry that there will be an uptick in stress-related disorders including depression, anxiety, substance abuse and post-traumatic stress disorder.

Though Congress is considering a bill to expand Medicare and Medicaid coverage of telehealth services from therapists and social workers in an attempt to begin tempering a possible mental-health crisis, mental health organizations still question the already-overwhelmed healthcare systems capacity to aid Americans when the quarantine is over.

Healthcare and government officials alike warn that a mixture of social distancing, exposure to death-related trauma, unemployment and other factors are expected to contribute to an increase of mental-health disorders among Americans for many years to come.

In the meantime, viral social media posts point to feelings that many people share.

For example, not knowing what day it is:

Or, the toils of trying to attend school from home:

And having to work alongside family members for the first time:

While hard data about the rates of mental illness during the pandemic are not yet available, there is plenty to suggest that people are looking for ways to cope with the excess of time that they are spending at home. According to Google Trends data, U.S. searches for the words positivity, self-care, baking and painting reached peak popularity in April.

There is scientific evidence that creating art has cognitive benefits. A growing body of research suggests that art therapy, or the practice of treating patients with mental health disorders with art-related activities, can reduce stress and anxiety as well asimprove symptoms of neurological and age-related disorderssuch as dementia and Alzheimers.

Researchers have foundthat painting, drawing, sculpting and even scribbling have the ability to stimulate the centers in the brain related to pleasure and reward. Psychotherapists, hospitals and schools across the country have adopted art therapy methods with positive results.

The practice has also been used on non-cognitive disorders. Mayo Clinics Slaggie Family Cancer Education Center offers art therapy to its patients. One of the reasons art therapy is helpful is because it can be used as a tool for self-expression and working through feelings; it is a way to convey emotions, hopes and concerns. While making art, the creative corner of the brain takes over, Megan Roessler, a staff member at the Slaggie Center,wrote in a blog post.

But if creating art is not your forte, similar benefits have been found for simply viewing art. Some researchers have found that browsing through an art gallery can help lower the bodys concentration of the stress hormone cortisol and increase that of the pleasure hormone dopamine.

While there may not be a way to physically access your favorite Smithsonian museum in the current climate, there is still plenty of art waiting to be viewed online. Some of the worlds most acclaimed museums are offering online access to some of their exhibits.The Louvreand theVatican Museumhave stunning virtual tours. Other museums, including theMetand theNational Gallery, are allowing visitors to access interactive photo galleries.

In addition, the hashtags#covidartand#covidartmuseumhave amassed more than 100,000 posts on Instagram. Artists from all over the world are connecting by sharing their creations via these hashtags. And you dont have to scroll far to find a piece thats relatable to what you may be going through.

Maybe youre feeling thankful for our healthcare workers:

Or looking for a way to escape the confines of your home:

Or reminiscing about that quarantine cut youre already regretting:

Or even laughing to keep from crying:

So consider picking up a paintbrush or viewing someone elses creations online. You may be surprised to find that art-related activities are effective stress relievers for you. Regardless,prolonged activation of the bodys stress system is harmful. There are countless other activities that have stress-relieving effects, including exercising and viewing nature. During this time, it is important to find ones that are effective for you.

This article is reprinted with permission from Capital News Serivce

The Southern Maryland Chronicle is a local, small business entrusted to provide factual, unbiased reporting to the Southern Maryland Community.While we look to local businesses for advertising, we hope to keep that cost as low as possible in order to attract even the smallest of local businesses and help them get out to the public. We must also be able to pay employees(part-time and full-time), along with equipment, and website related things. We never want to make the Chronicle a pay-wall style news site.

To that end, we are looking to the community to offer donations. Whether its a one-time donation or you set up a reoccurring monthly donation. It is all appreciated. All donations at this time will be going to furthering the Chronicle through hiring individuals that have the same goals of providing fair, and unbiased news to the community. For now, donations will be going to a business PayPal account I have set-up for the Southern Maryland Chronicle, KDC Designs. All business transactions currently occur within this PayPal account. If you have any questions regarding this you can email me at [emailprotected]

Thank you for all of your support and I hope to continue bringing Southern Maryland the best news possible for a very long time. David M. Higgins II

Read more here:
How art can help relieve stress during social isolation - The Southern Maryland Chronicle

Recommendation and review posted by Bethany Smith

Healthcare for a whole range of non-life-threatening illnesses, from dentistry to physiotherapy, has been put on hold since the outbreak of coronavirus in Ireland, in both the public and private health system. The Irish Times asked readers to tell us how they have been affected. This is a selection of the responses we received.

Due to the sensitive nature of health information, some names have been withheld on request.

I have found three lumps in my breast and have family history my mother has had breast cancer twice and my first cousin is just finished treatment for it. I had an appointment in St Vincents Private for March 26th and it was cancelled. Nobody can tell me when I will be able to get an appointment now. I have health insurance. Three lumps and a family history of breast cancer, and I am not seen as urgent. Sarah Donohoe

I went in for cataract removal in the Mater Private on February 20th. While the cataract was removed, the IOL (intraocular lens) wasnt inserted as the timeline to complete it ran out. It was rescheduled for March 19th but the HSE took over the hospital and my procedure was postponed. I am still waiting to be called by my consultant, but am giving it little/no hope as she is prevented from operating on private patients. I am in limbo and dont know what to do. I cannot see through my right eye. Tom Kennedy

I am 72 and my scheduled April knee replacement was cancelled because the Santry clinic was commandeered by the HSE. The private hospitals now have a 15 per cent bed occupancy and the public side have an abundance of beds. My surgeon informs me that I will be added to the bottom of the public waiting list (no complaint with that) and he is unsure if the private hospitals will ever reopen. The pre-Covid waiting time for an elective public joint replacement was four years (two years for a consultation and two years on the surgery list). If I stop paying the family VHI I could buy a golf buggy and cope with my golf, or pay for the surgery in another country like Romania. The only reason for having private health insurance is to cover whats not provided in any meaningful sense by the HSE - joint replacement, cataracts and benign surgery and if you get cancer, a heart attack or a stroke just rock up to hospital and you get immediate excellent treatment. Dr Michael Foley

Im from Cork. I suffer from chronic pain as a result of complications from numerous surgeries. At the end of last year I moved to Spain to access medical cannabis while waiting on the license at home that my GP and pain consultant applied for. My license was just approved this week in Ireland, however now I am stuck in Spain and unable to access medical cannabis here. Alicia Maher

Having suffered from thyrotoxicosis as a result of Graves Disease for almost two years, I was due to receive a thyroidectomy on March 31st. I had been advised by various consultants that definitive treatment was required, as my condition was not responding well enough to anti-thyroid medication to allow me to reduce the dosage. This medication is not considered safe to continue for longer than 18 months due to increased risk of side effects. I have now been consuming a high dose for 21 months.

On March 26th, my surgery was cancelled until further notice. I remained hopeful that if the hospitals did not become overwhelmed, it might soon be considered safe for my procedure to go ahead. In the meantime, I was advised to continue with my routine blood tests (every six weeks) and to now request that my liver function and full blood count be checked. This week, I received a letter from my endocrinologist stating that my surgery will not proceed until the Covid-19 situation has ended completely.

In addition to this, I also suffer from Graves ophthalmopathy as a result of my auto-immune thyroid condition. This creates numerous difficulties in my day-to-day life including pain, sleep disruption, and interference to my vision. I was referred to an ophthalmologist last November, and in February received my appointment letter, dated for June. When I attempt to call this ophthalmologists clinic, I am met with a pre-recorded message stating that the clinic is closed and that I should not leave a voicemail as it will not be received.

I am a private patient and all treatment has therefore been within the private healthcare system. While I felt that the decision to have the countrys private hospitals operate publicly during this crisis was a fair one, I feel my healthcare for a condition I am actually currently suffering from, is being sacrificed for the potential healthcare of those who may suffer from Covid-19 in the future.

I am now at my wits end; I feel the money I pay for health insurance is now putting me at a disadvantage. Necessary healthcare, which is my right, is being withheld despite the hospitals in Cork not being overwhelmed by Covid patients. Michelle ORegan

I was diagnosed with prostate cancer on March 6th, and told that treatment would be either a prostatectomy, or radiology combined with hormone therapy. The prostatectomy was apparently ruled out by the specialist, due to the coronavirus emergency. I had a telephone consultation with the radiologist, who made an appointment for a CT scan for March 31st at 9.45am. I arrived at the hospital at 9.15. I got a call from the specialist as I arrived to say that the procedure had been cancelled. He subsequently sent a letter to my GP, copied to me, which said I think it is safe to defer his treatment until later in the summer.

My four-year-old daughter needs two teeth removed via general anaesthetic. She has been given two antibiotics and is on a third from a urinary infection she got from the antibiotics. This is going on a month and a half now and she cannot eat with pain. We are told that dentists cannot use general anaesthetic at the moment due to Covid restrictions! I have spent the month on the phone going from pillar to post with dentists, the HSE, and politicians.

My GP referred me publicly and privately for colonoscopy and scope due to ongoing symptoms, unaware these procedures have all been cancelled.

Had an appointment for Cappagh Hospital for March 24th. Cancelled at five days notice. Still no update as to when it will happen.

I had an appointment for a knee replacement in April, which was cancelled. I am in pain and on daily medications. I cannot walk 50 metres now.

I was due to have surgery in Galway Clinic on March 23rd. I got a call on Friday 20th to say the surgery had been cancelled, as the clinic had to close. I am in serious pain on a daily basis. I pay VHI.

I spoke with my GP last Thursday, who requested a referral to the breast clinic. I got a letter today with an appointment for next Tuesday. It was super efficient.

I was given blood tests from the GP, since I had not been feeling well. I was told I had a deficiency of B12, which probably explains some depression and no energy. I was told I needed two injections a week for three weeks, then every three months. This was put on hold due to virus.

Only a small issue, but I had samples sent away a month ago to confirm a fungal infection. I have not heard back yet, have had no blood tests as I was told would take place within two weeks, and no updates from GP. My toe is in bad way, and I have to clean it daily and be careful with walking/ footwear so as not to pull at the nail or damage it.

I have recently been diagnosed with prostate cancer. I have had the treatment options explained to me but there is no treatment available for anyone with prostate cancer during the Covid emergency. My cancer is at an early stage, and I am not in urgent need of treatment. I fully understand that my case has to wait until the crisis is resolved. The oncologist has promised to contact me in July to review the situation. If there is still no prospect of treatment at that time I will begin to be worried.

I have been diagnosed with a neurological condition called CIDP. I cannot get an appointment to see my consultant neurologist in his rooms. Martina OFlaherty

I am due to have an arthroscopy and surgery to repair my rotator cuff in my right shoulder, and steroid injections in both knees for pain/arthritis.

I cannot get a scan either public or private. My doctor has sent requests too both. I had a surreal conversation from the Mater Private Cork, who phoned me to say they cannot see me as a private VHI patient, I then offered to pay them directly, to no avail. They also could not see me as a public patient. When I asked how could they see me. The receptionist who was very nice said they were only scanning patients who were put forward by specialists who worked for the Mater Private. I know you might think a sinus is a small thing in todays world, but this is seriously infected. I am popping antibiotics like theres no tomorrow.

I have a familial tendency to bowel cancer, which my father died from in his 60s. I am 68. I have had a number of colonoscopies in recent years and on each occasion have had a number of pre-cancerous polyps removed. My last one was in February 2019 after which the surgeon told me to come back in a year. I had an appointment arranged for March 24th, but all colonoscopies were cancelled from that day onwards. I recently received an appointment for sometime in July, but I understand that this is just a possibility and that the HSE have given the hospital no dates on which they may resume. I am worried.

My surgery was due in April at the Blackrock Clinic, cancelled due to private hospital takeover. I am very disappointed. It is not life or death, but with 2.2 million people with private insurance, the HSE is causing another crisis. Remove private work from public hospitals and leave the private sector alone.

Link:
Healthcare on hold: I cannot see through my right eye - The Irish Times

Recommendation and review posted by Bethany Smith

INTRODUCTION:

The hobnail variant of papillary thyroidcancer(PTC) is rare. Intrathyroid parathyroid adenoma (ITPA) is also rare. Co-ocurrence of PTC and ITPA in the same thyroid lobe is extremely rare. Likewise, primary hyperparathyroidism with such non-medullary thyroid carcinoma is rare. The specific molecular profile of hobnail PTC (HPTC) is different from the classic, poorly differentiated and anaplastic variants and may contribute to its aggressive behavior. HPTCs genetic profile remains unclear.

A 61-year-old woman presented to our endocrine clinic with generalized aches, bone pain, polyuria, and right neck swelling of a few months duration. Laboratory findings revealed hypercalcemia and hyperparathyroidism. Ultrasound of the neck showed 4.6cm complex nodule within the right thyroid lobe. Sestamibi scan suggested parathyroid adenoma in the right thyroid lobe. Fine-needle aspiration (FNA) revealed atypical follicular lesion of undetermined significance. She underwent right lobectomy, which normalized the intraoperative intact parathyroid hormone levels. Final pathology with immunohistochemical stains demonstrated HPTC and IPTA (2cm each). Next-generation sequencing investigated the mutation spectrum of HPTC and detected BRAFV600E mutation.

A parathyroid adenoma should not exclude the diagnosis of thyroid carcinoma. Thyroid evaluation is needed for patients with primary hyperparathyroidism to prevent missing concurrent thyroid cancers. Cytomorphologic features to distinguish thyroid from parathyroid cells on FNA cytology must be considered. Immunohistochemical stains are important. BRAFV600E is the most common mutation in HPTC. This is possibly the first reported case of HPTC and ITPA co-occurring within the same thyroid lobe. Studies that define other molecular abnormalities may be useful as therapeutic targets.

View original post here:
First ever case report of co-occurrence of hobnail variant of papillary thyroid carcinoma and intrathyroid parathyroid adenoma in the same thyroid...

Recommendation and review posted by Bethany Smith

Vaginas: they give us pleasure, cause us pain, and literally give us life. They're pretty damn amazing, but how well do you actually know yours?

Sexual wellness is a massive part of self-care, and the best way to look after yourself is to know exactly what's going on down there. And we're all different, so normal for you might not be for your mates. Nerding up on your nethers isn't only a good idea to help you get maximum enjoyment from masturbation and sex (although, that is a very good reason), but also so that you can easily spot the signs if something feels off.

Worryingly, it seems a lot of people are still mystified by the vagina and the vulva (the external part of the genitals). A 2019 YouGov poll found that 45% of women and 59% of men couldn't even point out the vagina on a diagram of female genitalia. They were also asked to point out the clitoris, which thankfully 71% of women, and 69% of men correctly identified. That's still almost one in three women who don't know where their clitoris is though yikes.

But now that we're in lockdown with a lot of time of our hands, why not spend some of it getting better acquainted with your vagina? GLAMOUR is here to get you clued up on your down there, busting myths and dropping some pretty amazing facts too. And we're not just talking about vaginas, either. We've got the lowdown on the ins and outs (so to speak) of your labia, clitoris, perineum, G-spot, even the A-spot (yes, it's a thing) the whole lot.

So pull up a chair, maybe grab a mirror and get ready to learn 20 amazing vagina facts. If this inspires you to indulge in a little self-care/love read our expert tips on orgasming on your own or check out our roundup of the best sex toys out there. You're welcome.

Link:
20 Facts You Need To Know About Your Vagina And Vulva - Glamour UK

Recommendation and review posted by Bethany Smith

Weight loss relies on a fairly straightforward equation: To drop the number on the scale, you must consume fewer calories than your body burns. With this in mind, it seems logical that cutting as many calories as possible can help you shed pounds faster. Makes sense, right?

News flash: Your weight-loss diet shouldn't leave you starving.

Image Credit: AndreyPopov/iStock/GettyImages

Hate to break it to you, but this calorie-slashing strategy may actually be sabotaging your efforts. In fact, eating too far below your specific calorie needs not only halts weight loss but may also negatively affect your health.

The rub is that everyone's calorie needs are different, so there's no one-size-fits-all when it comes to calorie counts for weight loss.

Here, Lisa Moskovitz, RDN, dietitian and founder of The NY Nutrition Group, helps you identify red flags that indicate you're not eating enough, plus offers guidance on how to determine the right number of calories you personally need for healthy, safe weight loss.

In general, women shouldn't cut their calories below 1,200 a day and men should stay above 1,500 unless they're under the supervision of a health care professional.

When you begin a weight-loss plan, your body might need time to adjust to eating fewer calories, so a hunger pang here or there is common. But if you're constantly craving your next meal or snack after a few days, something might be up.

"Thinking about food all the time is a sign your body needs more," Moskovitz says. That could mean more calories and/or a better balance of food groups to supply all necessary nutrients.

In other words, your diet might be lacking in major macros like carbohydrates, fats and proteins or other filling nutrients like fiber, which can keep your blood sugar stable and appetite in check.

That's why it's essential to heed your hunger cues. "Even if you think you ate enough based on specific portions, that doesn't mean your body agrees," Moskovitz says.

Lightheadedness is another indication that you're not eating enough. "Your blood sugars may be too low and thus causing you to feel weak or woozy," Moskovitz explains.

That's because when your blood sugar dips below what your body needs to function properly, your systems go into conservation mode to use less energy, according to Harvard Health Publishing.

This faint feeling may also be a result of dehydration, Moskovitz says. Without sufficient water, your blood volume decreases, leading to a decline in blood pressure, per Harvard Health Publishing. When this happens, your brain doesn't get enough blood, causing dizziness.

With that said, it's always a good idea to talk to your doctor if you experience these symptoms to be sure that you're not dealing with a more serious underlying health condition, Moskovitz says.

If your workouts are tougher than usual, you may need to evaluate what and how much you're eating.

Image Credit: Tero Vesalainen/iStock/GettyImages

Wiped out during workouts? Poor performance in the gym is a hallmark of consuming too little food, Moskovitz says.

Here's why: Calories equal energy, so if you're not ingesting an adequate amount, your body must use all its strength to support basic functions and it won't have much oomph left over for anything extra, including your workouts.

Not only does undereating sap your energy, it also curbs your ability to build lean muscle, Moskovitz adds. Since muscle burns more calories than fat, even at rest, having more of it aids weight loss.

Remember, to gain muscle, you need to pack plenty of protein onto your plate, per the American College of Sports Medicine. If you're over-restricting calories, though, odds are you're not getting enough of the macronutrient.

If you're in a calorie deficit, you should be aiming for 1.3 grams of protein per kilogram of body weight (a kilogram is about 2.2 pounds, for the record).

A diet that's too low in calories can leave you backed up.

"Not eating enough means there is nothing to push through your digestive tract, which can lead to bowel movement irregularities such as constipation," Moskovitz says.

Plus, a lot of trendy diets ditch (or significantly cut) carbs including healthy whole grains, veggies and fruits which are full of fiber. The thing is, fiber bulks up your poop and helps food pass from your stomach to your intestines, per the U.S. National Library of Medicine. So, without enough of it, your stool gets, well, sort of stuck.

To avoid this and speed up your stool, Moskovitz recommends eating at regular intervals throughout the day with plenty of gut-healthy fiber as well as hydrating with water to keep things moving smoothly.

Psst: A study published February 2015 in the Annals of Internal Medicine found that simply aiming to eat 30 grams of fiber each day could help you lose weight as effectively as a more complicated diet.

If your weight loss grinds to a halt, you might think that slashing more calories is the solution. It's probably not.

Though it sounds counterintuitive, your low-calorie diet could be the reason you've stopped shedding pounds in the first place.

"Whenever you limit calories to lose weight, your metabolism can go through a process called adaptive thermogenesis," Moskovitz says. When this happens, your metabolism may slow down.

Essentially, when you cut too many calories, your body goes into survival mode, so it burns fewer calories to preserve energy. In short, your body is protecting you from what it perceives as starvation.

To make matters worse, restrictive dieting may even raise your levels of cortisol, a stress hormone linked to increased appetite and belly fat, according to a May 2010 study published in Psychosomatic Medicine.

Too-few calories can leave your immune system in the lurch.

Image Credit: PeopleImages/E+/GettyImages

Catching colds regularly? Your low-calorie diet may be to blame.

"Eating too little can negatively affect the immune system and stress out the body," Moskovitz says.

When this happens, your body produces fewer lymphocytes, aka infection-fighting white blood cells, according to the Cleveland Clinic. Consequently, with lower lymphocyte levels, you run a greater risk of getting sick.

What's more, restrictive dieting "usually means you're not getting key immune-building nutrients like vitamin C, zinc, vitamin D and probiotics," Moskovitz adds.

Put simply, your body's defenses suffer when you cut too many calories in the form of wholesome, nutritious foods.

First, determine the number of calories you should be eating each day to maintain your weight by using the chart in the Dietary Guidelines for Americans, which breaks it down by age, sex and physical activity level.

For healthy weight loss (about 1 pound per week), you should aim to cut about 500 calories a day from that amount, according to the Mayo Clinic. (As long as you're not falling below 1,200 calories for women or 1,500 calories for men.)

To make it even easier on yourself, you can download LIVESTRONG.com's MyPlate tracker, which will do the calculating for you. The app also makes it easy to update your needs as your weight and exercise regimen change.

Moskovitz suggests consulting with a registered dietitian, who can take a look at your complete medical, lifestyle and diet history. A nutrition expert can also help you devise a proper meal plan to ensure you get the nutrients you need when cutting calories.

Link:
6 Signs Youre Not Eating Enough Calories on Your Weight-Loss Diet - LIVESTRONG.COM

Recommendation and review posted by Bethany Smith

InForGrowth Market Research offers a most recent distributed report on Global Adenomyosis Treatment industry examination and figure 2019-2025 conveying key bits of knowledge and giving an upper hand to customers through a point by point report. The report contains XX pages which profoundly displays on current market investigation situation, up and coming just as future chances, income development, evaluating and gainfulness. The Global pandemic of COVID19 calls for redefining of business strategies. This Adenomyosis Treatment Market report includes the impact analysis necessary for the same

Download Sample Table of Content PDF of COVID-19/CoronaVirus Impact Analysis of Adenomyosis Treatment Market 2020. https://inforgrowth.com/CovidImpact-Request/6322440/adenomyosis-treatment-market

Worldwide Adenomyosis Treatment Market inspect reports consolidate market designs nuances, genuine scene, feature assessment, cost structure, capability, bargains, net advantage, and movement and measuring of business.

Major Key players covered in this report:Bayer AG, Ferring B.V, Johnson & Johnson, Novartis, Merck, Pfizer, Contura.

Adenomyosis Treatment Market Potential

The overall market is set up for energetic advancement with progressively moving of various gathering methodology to more affordable objectives in rising economies. Another factor booked to altogether bolster the market is fused programming game plans disposing of the prerequisite for different models and thing survey concerns.Premium Insights on Adenomyosis Treatment Market 2020 with Market Players Positioning; Download Free Sample Copy: https://inforgrowth.com/sample-request/6322440/adenomyosis-treatment-market

The Worldwide Market forGlobal Adenomyosis Treatment marketis relied upon to develop at a CAGR of generally xx% throughout the following five years, will arrive at xx million US$ in 2026, from xx million US$ in 2019, as per another research.

This report focuses around the Adenomyosis Treatment Market in the worldwide market, particularly in North America, Europe and Asia-Pacific, South America, Middle East, and Africa. This Adenomyosis Treatment Market report sorts the market dependent on the manufacturer, region, type, and application.

Major Classifications of Adenomyosis Treatment Market:

By Applications: Hospital, Clinic, Others

The study objectives of Adenomyosis Treatment Market Report are:

Regional Analysis of Adenomyosis Treatment Market:

The report additionally provides a local examination of the market with a high focus on showcase development, development rate, and development potential. The research report calculates marketplace length estimation to analyze investment possibilities and destiny growth. The key players and distinctive affecting components are examined completely on this report.

Enquire before Purchase this report at https://inforgrowth.com/enquiry/6322440/adenomyosis-treatment-market

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:Address: 6400 Village Pkwy suite # 104, Dublin, CA 94568, USAContact Name: Rohan S.Email:[emailprotected]Phone: +1-909-329-2808UK: +44 (203) 743 1898Website: http://www.inforgrowth.com

Read more here:
Adenomyosis Treatment Market 2020: Potential Growth, Challenges, and Know the Companies List Could Potentially Benefit or Loose out From the Impact of...

Recommendation and review posted by Bethany Smith

DUBLIN--(BUSINESS WIRE)--The "Global Stem Cell Therapy Market By Type (Allogeneic, Autologous, Syngeneic), By Source of Stem Cells (Adipose Tissue, Bone Marrow, Neural, Embryo/Cord Blood derived, iPSCs, Others), By Application, By End Users, By Region, Forecast & Opportunities, 2025" report has been added to ResearchAndMarkets.com's offering.

The Global Stem Cell Therapy Market is expected to grow at a formidable rate of around 12% during the forecast period. The industry is segmented based on type, source of stem cells, application, end-users, company and region.

The market is driven by the growing popularity and awareness pertaining to the use of stem cells for the prevention and cure of certain life threatening diseases. Additionally, increase in number of stem cell banks and growing investments by the government and private organizations for the development of stem cell preservation infrastructure is further propelling the market across the globe.

Based on type, the market can be categorized into allogeneic, autologous and syngeneic. The allogenic type segment is expected to register the highest growth during forecast period attributable to the rising commercialization of allogeneic stem cell therapy products, wider therapeutic applications of allogeneic stem cells, easy production scale-up process, growing number of clinical trials related to allogeneic stem cell therapies, among others.

Based on end-users, the market can be bifurcated into hospitals and clinics. The hospitals segment is expected to dominate the market during the forecast years. This can be accredited to the rising preference for stem cell therapies offered by hospitals proves beneficial for the business growth. Hospitals have affiliations with research laboratories and academic institutes that carry out research activities for developing stem cell therapies. On introduction and approval of any novel stem therapy, hospitals implement it immediately.

Regionally, the stem cell therapy market has been segmented into various regions namely Asia-Pacific, North America, South America, Europe, and Middle East & Africa. Among these regions, North America is expected to dominate the overall stem cell therapy market during the next five years on account of the increasing number of clinical trials for stem cell-based products and increasing public-private funding & research grants.

Major players operating in the Global Stem Cell Therapy Market include Osiris Therapeutics, Inc., MEDIPOST Co., Ltd., Anterogen Co., Ltd., Pharmicell Co., Ltd., Holostem Terapie Avanzate S.r.l., JCR Pharmaceuticals Co., Ltd., NuVasive, Inc., RTI Surgical, Inc., AlloSource, Thermo Fisher Scientific and others. The companies are developing advanced technologies and launching new services in order to stay competitive in the market.

Years considered for this report:

Objective of the Study

Key Topics Covered

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global Stem Cell Therapy Market Outlook

5.1. Market Size & Forecast

5.1.1. By Value

5.2. Market Share & Forecast

5.2.1. By Type (Allogeneic, Autologous, Syngeneic)

5.2.2. By Source of Stem Cells (Adipose Tissue, Bone Marrow, Neural, Embryo/Cord Blood Derived, iPSCs, Others)

5.2.3. By Application (Musculoskeletal, Wound & Injury, Cardiovascular Disease (CVD), Surgery, Acute Graft-Versus-Host Disease, Drug Discovery & Development, Others)

5.2.4. By End Users (Hospitals v/s Clinics)

5.2.5. By Company (2019)

5.2.6. By Region

5.3. Product Market Map

6. Asia-Pacific Stem Cell Therapy Market Outlook

7. Europe Stem Cell Therapy Market Outlook

8. North America Stem Cell Therapy Market Outlook

9. South America Stem Cell Therapy Market Outlook

10. Middle East and Africa Stem Cell Therapy Market Outlook

11. Market Dynamics

11.1. Drivers

11.2. Challenges

12. Market Trends & Developments

13. Competitive Landscape

13.1. Osiris Therapeutics, Inc.

13.2. MEDIPOST Co. Ltd.

13.3. Anterogen Co. Ltd.

13.4. Pharmicell Co. Ltd.

13.5. Holostem Terapie Avanzate S.r.l.

13.6. JCR Pharmaceuticals Co. Ltd.

13.7. NuVasive, Inc.

13.8. RTI Surgical, Inc.

13.9. AlloSource

13.10. Thermo Fisher Scientific

14. Strategic Recommendations

For more information about this report visit https://www.researchandmarkets.com/r/hmawq6

Here is the original post:
Global Stem Cell Therapy Market Forecast & Opportunities, 2025 - ResearchAndMarkets.com - Business Wire

Recommendation and review posted by Bethany Smith

MIKE TYSON has been doing the rounds to physically prepare for his sensational boxing comeback aged 53.

Tyson, who retired in 2005, has a whole new diet and cardio regime as well as going through a "weird" stem cell treatment.

3

It comes after the former heavyweight king announced plans to make a return to the ring to compete in exhibition bouts for charity, and has been training for the last month to do so.

Speaking to rapper LL Cool J on the Rock the Bells Radio show on SiriusXM, Tyson explained the methods he is using to get back into fighting shape, as he revealed: "Really I would just change my diet and just do cardio work.

"Cardio has to start, you have to have your endurance to go and do the process of training.

"So something to do is get in cardio, I would try and get two hours of cardio a day, make sure you get that stuff in. Youre gonna make sure youre eating the right food.

"For me its almost like slave food. Doing what you hate to do but doing it like its nothing. Getting up when you dont want to get up.

"Thats what it is. Its becoming a slave to life.

"Being a slave to life means being the best person you can be, being the best you can possibly be, and when you are at the best you can possibly be is when you no longer exist and nobody talks about you. Thats when youre at your best."

Tyson's return to training for the first time in 15 years has been aided by stem-cell research therapy, that has left him feeling like a "different person".

Stem-cell therapy is the use of stem cells to treat or prevent a disease or condition that usually takes the form of a bone marrow transplantation.

Tyson was asked whether that meant if his white blood had been spun and then put back in, to which he replied: "Yes. As they took the blood it was red and when it came back it was almost transfluid (sic).

"I could almost see through the blood, and then they injected it in me.

"And Ive been weird ever since, Ive got to get balanced now."

Having previously claimed he feels in the best shape of his life, Tyson revealed he will be ready to fight again in just six weeks.

He said: "My mind would belong to somebody that disliked me enough to break my soul, and I would give them my mind for that period of time.

"Six weeks of this and Id be in the best shape Ive ever dreamed of being in. As a matter of fact, Im going through that process right now. And you know what else I did, I did stem-cell research."

WHAT IS STEM CELL TREATMENT USED FOR?

Stem cell transplants are carried out when bone marrow is damaged or isnt able to produce healthy blood cells.

It can also be used to replace damaged blood cells as the result of intensive cancer treatment.

Here are conditions that stem cell transplants can be used to treat:

GARDEN PARTYEddie Hearn reveals plan to bring boxing back by hosting fights in his GARDEN

NO W-HAYEHaye snubs Mike Tyson in top 5 heavyweights of all time and details sad decline

Revealed

MONEY MIKEMike Tyson's earnings from all his major fights revealed as he raked in 557m

Exclusive

SON OF A GUNTeddy Atlas lost 30m after holding gun to Mike Tyson's head when he was 15

BLOOD SPORTMike Tyson injected by docs with translucent blood that made him feel 'weird'

WEATHER THE STORMMayweather demands 500MILLION to make stunning boxing return

TONE IT DOWNTyson Fury is No1 in world but Anthony Joshua would beat him says Bellew

GYPSY SWINGFury names his next THREE fights as he refuses to pay Wilder to step aside

Rich MikeWhat is Mike Tyson's net worth and how does he earn cash now?

During his reign as champion, Tyson would wake up at 4.30am to run before later heading to the gym where he would do 10-12 rounds of boxing mixed in with an array of muscles exercises.

His diet consisted of 3000-4000 calories of carbohydrates and proteins which helped fuel his training sessions.

Tyson, still the youngest heavyweight champion of all time at 20, retired with a record of 50-6-2 and remains one of the most celebrated punchers of all time.

3

3

Read the original post:
How Mike Tyson is in such incredible shape at 53 thanks to new diet, cardio and weird stem cell tre - The Sun

Recommendation and review posted by Bethany Smith

Brian Lindberg

Lockheed Martin Corporation has partnered with Be The Match to enable patients to continue receiving life-saving transplants without interruption during the COVID-19 pandemic by ensuring the timely delivery of bone marrow and blood stem cells for transplant, Lockheed Martin reported on Thursday.

"The incredible support from Lockheed Martin is a lifeline to our patients. For those awaiting bone marrow transplant, their very survival depends on the on-time delivery of these life-saving cells. By offering flight services, Lockheed Martin is helping us ensure that patients can continue the cells they need, exactly when they need them," said NMDP/Be The Match Chief Policy Officer Brian Lindberg.

With Lockheed Martins donation of the companys corporate aircraft, the National Marrow Donor Program (NMDP)/Be The Match was able to support the federal government's COVID-19 response and relief efforts and ensure patients that life-saving products from European donors would arrive on time.

Under the partnership, Lockheed Martin will provide weekly air transport based on government medical need. The company will fly government medical teams to the most critical, high-priority locations around the country. In addition, Lockheed Martin will transport materials to support bone marrow transport to help with the government's COVID-19 response.

In addition to matching donors and patients, one of the program's primary missions is coordinating the delivery of bone marrow domestically and internationally to patients in the United States and abroad.

Marillyn Hewson, CEO, chairman and president of Lockheed Martin and 2020 Wash100 Award recipient, recently released the companys efforts to remediate the effects of the global pandemic. In April 2020, Hewson noted that Lockheed Martin has projected that it will be able to flow down over $450 million in accelerated payments to its supply chain partners.

The funding will support those who are critical to supporting the economy and national security. Lockheed will continue its work with the Department of Health and Human Services and provide air transport of government medical teams to the most critical, high-priority locations around the country. The company also pledged $10 million in charitable contributions for COVID-19 relief and recovery efforts.

The company has donated $2 million to Project HOPE to help deliver personal protective equipment to the Federal Emergency Management Agency for distribution to America's doctors, nurses, and first responders. Lockheed also donated $2 million to the American Red Cross to support military personnel, veterans, and families and $2 million to the CDC Foundation All of Us to combat Coronavirus emergency response fund.

As we continue to face this unprecedented crisis, Lockheed Martin is driven by our commitment to the mission of our U.S. and allied customers. We will continue to maintain our operations for our men and women in uniform and we are resolved to find additional ways to contribute to the relief and recovery from COVID-19, Hewson noted.

About Lockheed Martin

Headquartered in Bethesda, Maryland, Lockheed Martin is a global security and aerospace company that employs approximately 110,000 people worldwide and is principally engaged in the research, design, development, manufacture, integration and sustainment of advanced technology systems, products and services.

Read more here:
Lockheed Martin Partners with Be The Match to Expedite Delivery of Transplants During COVID-19 Pandemic; Brian Lindberg Quoted - ExecutiveGov

Recommendation and review posted by Bethany Smith

PERTH, Australia Australian stem cell company Mesoblast Ltd. completed a capital raising of AU$138 million (US$90 million) to scale up manufacturing of its allogeneic cell therapy, remestemcel-L, to treat COVID-19 acute respiratory distress syndrome (ARDS).

The Melbourne-headquartered company is currently enrolling patients in a randomized placebo-controlled phase II/III trial in up to 300 patients across 30 sites in the U.S. The trial is evaluating whether remestemcel-L can reduce the high mortality in COVID-19 patients with moderate to severe ARDS.

Patients are being dosed, and were really pleased how fast enrollment is growing, Mesoblast CEO Silviu Itescu told BioWorld. Were right on target and hope to update the market soon.

The phase II/III trial was initiated after promising results were seen with remestemcel-L under an emergency compassionate-use protocol in COVID-19 ARDS at Mount Sinai Hospital in New York, where nine of 12 (75%) ventilator-dependent patients were able to come off ventilators within 10 days.

Under the compassionate-use protocol, patients in intensive care units received standard-of-care treatment. Once they were intubated on a ventilator, they were treated within 72 hours with two infusions of Mesoblasts remestemcel-L cells within five days.

Once youre ventilated when you have acute respiratory distress syndrome in the lungs, your likelihood of coming off a ventilator is 9%, and your survival is 12%, Itescu said.

Whats exciting is that our patients in the same epicenter of this disease with the same treatment everyone else is getting, suddenly 75% are coming off of ventilators within 10 days, and weve got 83% survival, Itescu said.

The compassionate-use treatment experience informed the design of the phase II/III trial, and the FDA approved the same protocol, but it is powered so that results will be self-evident, Itescu said.

The phase II/III trial will randomize up to 300 ventilator-dependent patients in intensive care units to either remestemcel-L or placebo on top of standard of care, in line with guidance provided by the FDA. The primary endpoint is all-cause mortality within 30 days of randomization, with the key secondary endpoint being the number of days alive and off mechanical support.

What people are dying of is acute respiratory distress syndrome, which is the bodys immune response to the virus in the lungs, and the immune system goes haywire, and in its battle with the virus it overreacts and causes severe damage to the lungs, he said.

Capital raise allows scale up for COVID-19 and influenza

The capital raise consisted of a placement of 43 million shares to existing and new institutional investors at a price of AU$3.20 per share, representing a 7% discount to the five-day volume-weighted average price (VWAP) at the close of trading May 8. The placement was conducted with Bell Potter Securities as lead manager and underwriter. Settlement is expected to occur on Friday, May 15.

Most of the funds raised will be used to scale up manufacturing of remestemcel-L for the treatment of critically ill patients suffering with diseases causing ARDS, including COVID-19 and influenza.

Were in the middle of a pandemic, and people are talking about opening up, and theyre talking about a potential second wave, Itescu said. Its too early to talk about projections, but we need to at least be in a position to make more product in an additional facility, so that requires technology transfer and certain process improvements.

Remestemcel-L is Mesoblasts lead product, and it is currently being studied in multiple indications so the move to ramp up manufacturing is a good strategic move regardless of COVID-19, he said.

There are at least 125,000 patients every year in the United States with influenza-related acute respiratory distress syndrome in intensive care units, and those patients have got about a 40% fatality rate. Up to about 60,000 patients die per year due to influenza ARDS, so even if COVID-19 magically disappears, which we could only hope, influenza is here to stay despite vaccines being available, the CEO said.

This product would work in the same way for influenza-related ARDS as it would for COVID-19-related ARDS, he said.

The ability to build out manufacturing capacity is part of an FDA requirement to be able to demonstrate it can make product for patients in the U.S.

The company already has a manufacturing facility in Singapore, and the additional site in the U.S. would give the company the ability to provide product globally.

Were putting our strategic plan into play. You need to have multiple geographies, especially in this kind of environment, Itescu said.

Without the cash, we wouldnt have been able to deliver on this, but we now can execute.

Mesoblast's allogeneic candidates are based on mesenchymal lineage cells collected from the bone marrow of healthy adult donors.

Remestemcel-L is currently being reviewed by the FDA for potential approval in the treatment of children with steroid-refractory acute graft-vs.-host disease (aGVHD). The company submitted the final module of a rolling BLA in January. The FDA has set a PDUFA date of Sept. 30 for the product branded as Ryoncil.

The clinical data submitted with the BLA showed a survival rate of 79% compared to an expected 30% survival rate in the pediatric phase III trial in aGVHD.

Remestemcel-L is also being developed for other rare diseases. Mesoblast is completing phase III trials in advanced heart failure and chronic low back pain.

Mesoblast shares (ASX:MSB) were down 1.45% on the news, trading at AU$3.39 per share by market close May 13. On Nasdaq (MESO), shares closed at $12.15.

View original post here:
Australia's Mesoblast raises $90M to scale up stem cell therapy manufacturing to treat COVID-19 ARDS - BioWorld Online

Recommendation and review posted by Bethany Smith

The novel coronavirus cant be killed or stopped with the current drugs that we have, the WHO said earlier this week. Dr. Anthony Fauci said separately that its virtually impossible to eradicate the virus. But there are plenty of therapies that can be used to reduce the severity of COVID-19 and shorten the recovery period.

The WHO is studying four or five of the best drugs for the new illness, but there are plenty of new lines of therapy that are discovered on a regular basis. The latest one consists of a treatment thats usually given to Duchenne muscular dystrophy patients.

Cedars-Sinai doctors have given six patients an experimental treatment consisting of cells grown from human heart tissues, according to ABC7. This therapy improved the overall condition of all patients, each of whom were critically ill before the Hail Mary treatment was administered. Four of them have come off ventilators and were discharged, while the other two are still in the hospital, but theyre alive.

Dr. Eduardo Marban and his colleagues were using the treatment for muscular dystrophy patients with heart failure before considering it for COVID-19. The novel coronavirus can do severe damage to the heart, and that may have been the reason why the doctors attempted this novel therapy.

This can only be considered anecdotal evidence at best, but the doctors are hoping that the FDA can approve a more extensive study that can evaluate the benefits of the therapy. The doctors have additional doses available in the freezer for the research.

Cells grown from human heart tissues sound a lot like stem cells, although the report doesnt refer to them as such. This wouldnt be the first time that stem cell use would prove to be helpful in COVID-19 cases. A few weeks ago, doctors from Mount Sinai reported theyve treated 12 patients using stem cells derived from bone marrow, and the therapy allowed 10 of them to come off ventilators. Those physicians also noted that further study is required.

Marban and his colleagues detailed the benefits of injections of cardiac progenitor cells (cardiosphere-derived cells or CDCs) for patients with muscular dystrophy in February 2018. Cardiosphere-derived cells are stem cells derived from cardiac tissue.

We unexpectedly found that treating the heart made the whole body better, Marban said at the time. These basic findings, which have already been translated to clinical trials, rationalize why treating the heart may also benefit skeletal muscle function in boys and young men with Duchenne.

The study showed the stem cells acted not just on the heart tissue, but also on skeletal muscle, and that the benefits persisted. We found that within a few weeks, the injected cells were undetectable, Marban said, but the benefits persisted for at least three months, which led us to discover that exosomes secreted by CDCs are responsible.

The same type of therapy was likely used to treat COVID-19 patients.

Image Source: John Minchillo/AP/Shutterstock

Chris Smith started writing about gadgets as a hobby, and before he knew it he was sharing his views on tech stuff with readers around the world. Whenever he's not writing about gadgets he miserably fails to stay away from them, although he desperately tries. But that's not necessarily a bad thing.

See more here:
Doctors just discovered another promising coronavirus therapy - BGR

Recommendation and review posted by Bethany Smith

Video

PUBLISHED: 06:30 16 May 2020 | UPDATED: 08:30 16 May 2020

James Barham was diagnosed with aggresive leukaemia five weeks after the birth of his son. He has raised more than 18k for the NNUH while undergoing chem at the hospital. Picture: James Barham

James Barham

Email this article to a friend

To send a link to this page you must be logged in.

On April 2 his first child, Charlie, was born at the Norfolk and Norwich University Hospital (NNUH).

Four weeks later, on Monday May 4, the builder from Drayton got out of bed and blacked out.

The 31-year old went to A&E that day for blood tests and the next day went back to the NNUH for a bone marrow biopsy.

Just 10 minutes after leaving the hospital, he had a call. Mr Barham had an aggressive blood cancer called acute myeloid leukaemia.

We were devastated, Mr Barham said. I was in absolute bits and just couldnt believe it.

Just four days before Charlie was born, Mr Barham said he started feeling nauseous but put it down to nerves ahead of the his sons birth.

It was a long birth and a bit traumatic, he said.

He then started feeling tired but thought it was the stress of having a new baby.

Last Wednesday, the day after he was diagnosed with leukaemia, he was back at the NNUH to start weeks of chemotherapy.

No visitors are allowed because of coronavirus, but staff on Mulbarton ward have moved him to a window bed so he can see his wife Katie and Charlie through the window.

But the new dad has not let the devastating news, or visiting restrictions, get him down.

He launched a charity head shave appeal on Facebook last week to raise funds for the hospitals cancer department and encouraged friends and family to join in.

I thought it would be an opportunity to give back, Mr Barham said.

Im going to be losing my hair anyway and everyone else is in lockdown and not had a haircut for weeks so I thought their friends and family could sponsor them for a head shave too.

Mr Barham lost his locks on Wednesday and has been joined by around 50 other head shavers.

In just over a week he has smashed his target of 6,000.

More than 18,000 has now been donated to the NNUHs charity from 800 people across the world through the Just Giving website. They have had donations from the US, Italy as well as his wifes native Australia.

I wouldve been over the moon if we had raised 2,000, he said. I have got messages from people in the US and India just giving their support.

All donations will go to the NNUHs cancer department, with staff deciding how best they can use it, he said.

The ex-Taverham High School pupil said doctors had told him the cancer was unlikely to be killed by chemotherapy, meaning he will need a stem cell transplant at Addenbrookes Hospital in Cambridge.

Im fit and healthy but this cancer comes up so rapidly and can kill someone. That is what has been the most surprising thing for me, he said.

On his Just Giving fundraising page, he wrote: I have a long journey ahead of me with leukaemia as my new temporary normal.

The constant care and attention Im receiving while Im in hospital is truly exceptional, all from men and women who are overworked and seriously underpaid.

Im now in their hands, so its the least I can do to try and help them back in a small way. Your support will be greatly appreciated. Lets all go forward and be kind to one another.

Louise Cook, head of fundraising at the NNUH, said: We are incredibly grateful for the support and fundraising James, his family and friends are undertaking at this difficult time.

We are overwhelmed at the support shown to the hospital charity, where the money raised will go to support our work with cancer patients. We wish to say thank you to everyone who has got behind James fundraising.

You can donate to Jamess headshave at http://www.justgiving.com/fundraising/james-barham3

A leukaemia which comes with little warning

The NHS says symptoms of acute myeloid leukaemia (AML) can come on suddenly.

They include feeling tired and weak, weight loss and breathlessness.

This blood cancer is caused by a DNA mutation in the stem cells in the bone marrow.

The NHS website says the mutation causes the stem cells to produce many more white blood cells than are needed.

The white blood cells produced are still immature, so they do not have the infection-fighting properties of fully developed white blood cells.

As the number of immature cells increases, the amount of healthy red blood cells decreases and causes the symptoms of leukaemia.

The NHS says it is not know what triggers the genetic mutation.

Patients are treated with chemotherapy or radiotherapy but if that does not work a bone marrow or stem cell transplant may be needed.

If you value what this story gives you, please consider supporting the Eastern Daily Press. Click the link in the yellow box below for details.

The rest is here:
Cancer treatment inspires new dad to raise 18k for NNUH with mass head shave - Eastern Daily Press

Recommendation and review posted by Bethany Smith

The coronavirus pandemic has caused significant changes and delays to treatment plans for many people battling cancer, who are more susceptible to the virus due to weakened immune systems, nationwide statistics show.

A survey conducted by The American Cancer Society Cancer Action Network in late March and early April found that half of more than 1,000 patients and survivors surveyed had seen their treatment interrupted in some way. Many are working with health care providers to alter their treatment plans skipping treatments, delaying therapies and surgeries, changing dosages and switching to virtual visits to lower their risk of exposure to the virus.

Thesurvey asked respondents about their experience accessing health care as a result of the pandemic, including the availability of appointments and services, and concerns about being able to safely get their treatments in the future. It found that27% of patients in active treatment said they have had their treatment delayed. Of those, 13% saidthey haveno clear timeline for whentreatment will resume.

Additionally, many cancer patients also have had their support systems ripped away, as they practice social isolation and see annual support events such as Relay for Life in southeastern Connecticut canceled.

Balancing risks

Approximately 20,300 people in Connecticut will be diagnosed with cancer in 2020 and 6,390 will die from the disease, according to Bryte Johnson, Connecticut Government Relations Director for American Cancer.

Andy Salner, medical director for the Hartford HealthCare Cancer Institute at Hartford Hospital, said cancer patients often have weakened immune systems, so may more easily contract the virus than someone without cancer. They alsomay developa more severe case ofthe COVID-19, the disease caused by the virus,and have a harder time fighting it.

Some cancers themselves, like multiple melanomas and most types of Leukemia, impact the immune system directly by altering blood cells. People with cancer might also be poorly nourished because cancer itself can make it hard to digest food, cancer cells can use up nutrients and cancer treatments like radiation therapy and chemotherapy can cause nausea and lack of appetite, according to the Cancer Action Network.

Radiation therapy, immunotherapy and chemotherapy also can lead to short-term immune system damage, and bone marrow or stem cell transplants that use high-dose treatments to kill cancer also may harm immune system cells for weeks to months, according to the American Cancer Society. Chemotherapy is the most common cause of a weakened immune system, because it causes a decrease in white blood cells, meaning a person's body won't be able to fight off infections as effectively.

At the Hartford Healthcare Cancer Institute in Waterford, oncologists Michael Kane and Sapna Khubchandani complete thousands of patient visits each year, and are helping patients design new treatment plansto battle and monitor their cancer while reducing their risk of exposure to the coronavirus.

For one local woman, a COVID-19 diagnosis meant missing her final session of chemotherapy, Khubchandani said. She did not identify the patient for privacy reasons.

Khubchandani said she didnt think missing one session so late in the treatment plan would have too much of an impact on the patient, but it wasnt ideal. An elective surgery related to the woman's cancer treatment, meant to take place after she completed chemotherapy, was delayed due to the virus, Khubchandani said.

COVID-19 has caused doctors to delay many suchnonemergency surgeries related to cancer treatment, including breast biopsies, lumpectomies or colonoscopies. Khubchandani, Kane and Salner all said they have had to make changes to surgery plans, either for patient safety or due to a lack of beds in intensive care units that are overwhelmed with patients battling the virus.

Doctors have been exploring alternatives, such as putting patients on hormonal treatment as they await surgery, so that were still treating the cancer while we wait, which will buy them time, Khubchandani said.

From some of his patients, Kane has made adjustments to medication dosages or administration intervals, to limit visits. Its all about individualizing treatment for each patients scenario, he said.

Worrying about the unknown

For one of Kane's patients, Richard van Etten ofHadlyme, protecting the 89-year-old from COVID-19 meant forgoing the transfusion he normally receives every three weeks.

Van Etten has been battling cancer since 2018, first in his bladder, then a cancerous module in his left lung, then in his lymph nodes.

Hecompleted chemotherapy and recently started a new drug called Keytruda, administered via infusions through a port for the cancer in his bladder and lymph nodes.

He recently learned that the cancer in his lymph nodes is gone, but his care team decided to continue his transfusions in case there were any residual cancer cells left, he said. But whenthe coronavirusbecame a concern, they decided to stop.

The virus hit and I was very hesitant about continuing my infusions, which were taking place in Waterford, he said. I talked with Dr. Kane and we decided to forgo them for now.

Since the start of the pandemic, he has been to the treatment center only once, to have his port cleaned. He said he is being very careful and is barely leaving his home, where he lives with his wife and daughter.

Van Etten said that he is absolutely anxious about contracting COVID-19, mostly due to his age. He said he feels confident about his decision to delay his treatment to limit his exposure to the virus but is worried about what might be happening inside his body.

Knowing that I was either in remission or close to it when I stopped, that it was at least temporarily under control, makes me feel OK with missing my infusions, he said. But that doesnt mean that in the back of my mind I dont wonder if it might be coming back.

Heis anxiously awaiting his next in-person visit, a PET scan scheduled for June 1, thats going to tell me whether any of the cancer has come back or not, he said.

Margie Elkins is a breast cancer survivor and active volunteer for the American Cancer Society and several other cancer organizations in southeastern Connecticut. While she is missing regular checkups and experiencing some delays in her own follow-up care, she said, One of the things that really worries me is not only the people who are experiencing delays in treatment but the people who have yet to be diagnosed, because the longer you wait in some cases, the larger the cancer becomes."

For thosewhose treatment hasbeen delayed, Its like their life is on hold because they dont know if their cancer is getting worse or getting better, she said.

Salner said delaying treatments certainly poses a risk. I think the worry would be that the cancer cells could potentially grow during that time (that treatments are delayed), that the treatment might be less effective if its delayed too far, he said.

Among survey respondents whose care had been canceled, delayed or changed by the pandemic, the most commonly impacted services were imaging procedures to monitor growth of cancer, supportive services such as therapy and in-person provider visits.

Salner said that decisions to delay chemotherapies and radiation, or reversing the order of treatments to prevent weakening of the immune system during the pandemic, were being made regularly and in partnership with patients and their families.

We want to balance making sure that we deliver the best cancer therapy possible but also place the patient at the lowest risk for getting what could be a life-threatening infection, he said.

In Waterford, Kane and Khubchandani have started screening patients for COVID-19 before starting them on chemotherapy or immunotherapy to ensure they are strong and healthy enough for the treatment. If a patient does have the virus, the doctors are delaying chemotherapy or immunotherapy in almost all cases. The ultimate decision though, is primarily left up to the patient. If they want to receive treatment, they likely will be able to, doctors agree.

Kane and Khubchandani also are implementing general precautions for people entering their offices: taking patients temperature, calling patients the day before to screen for COVID-19 symptoms and opting for virtual visits when possible. At the Waterford treatment center, theyve reduced the number of chairs in the waiting room and are scheduling laboratory services further apart. All doctors and patients are wearing masks at all times.

The extra precautions seem to be helping, Salner said. The Hartford Healthcare group has not seen a large influx of cancer patients testing positive for COVID-19.

Finding support

Some survivors are concerned about the emotional impact of COVID-19 on people currently battling cancer, worrying that they may feel overwhelmed and alone, both in their diagnosis and by social distancing.

Elkins said that she felt isolated when she was first diagnosed with stage1 breast cancer years ago, and can only imagine how that feeling is being compounded by the isolation of quarantine.

Greg Schlough, event chairman for the American Cancer Society Relay for Life of Southeastern CT, said that in his experience, cancer is a disease that causes people to really rally around you. The survivor saidthose with cancer tend to rely on their family and friends for support, like he did after being diagnosed with stage 3 melanoma on his 40th birthday in September 2000.

At the beginning, you get that doom and gloom feeling but when people start to come around and you start to see other people who have survived, you are able to say Hey, Im going to beat this thing. You know that you have people backing up and cheering you on, he said.

Right now, folks fighting cancer, especially a new diagnosis, may be struggling to find that support as they practice social distancing from their family and friends.

Schlough, in remission for 20 years, said that if he was a cancer patient right now, he would be afraid to go outside, and cant imagine how new patients are feeling.

For patients who are struggling with feelings of isolation or fear, events like the annual relay provide an opportunity to connect with others who are fighting the same fight, or who are examples of strength and survival. This years relay, which was set to be held on July 14 in Norwich, has been postponed indefinitely.

The annual fundraiser normally raises an average of $80,000 to $120,000 a year for the American Cancer Society, helping the society fund resources and support services to help people with cancer.

Schlough said organizers are hoping to reschedule the event for the end of summer, but it wouldfunction in accordance with social distancing guidelines and everyone will be required to wear masks. People currently in treatment, he said, may have to miss out or participate virtually.

Wed rather see them there next year smiling than this year with the risk of getting sick, he said.

Schloughsuggests patients or survivors who are emotionally strugglingor needhelp understanding treatment options shouldreach out to friends and family for over-the-phone support or call the American Cancer Societys hotline, 1 (800) 227-2345.

t.hartz@theday.com

Go here to see the original:
Higher risk of infection, changes to treatment makes COVID-19 a double threat for cancer patients - theday.com

Recommendation and review posted by Bethany Smith

Technology across the world is improving and innovatingwith time. Over the years, man-managed labor has almost finished from themarket and more and more technological and scientific gadgets are taking placemaking human labor more effective, efficient, and precise.

Medical science has also taken a lot of advantage fromthis scientific advancement therefore, we can say that doctors are making fulluse of science and technology and the world of medicine has evolved quiterapidly.

Orthopedic hospitalshave also seena remarkable transformation over time and the days when a regular orthopedicclinic only comprised of a few tools and a bad. The launch of innovativetechnologies, biologics, and hybrid items into the orthopedic industry isincreasingly growing.

Any of these emerging inventions gain regulatory approvalby showing significant equivalence to the US System of the Food and DrugAdministration (FDA) 510(k).

Surgeons play a key role in the implementation ofemerging technology to patients and will play a leading role in supportinghealthy, efficient, adequate, and cost-effective treatment, particularly forsurgical procedures. Surgeons will track and record the health results andadverse effects of their patients utilizing modern technologies and ensure thatthe new technology works as expected.

Ortho-biologics utilizes the regenerative ability ofcells in the human body. Ortho-biologics are created from compounds naturallypresent in the body which are used to facilitate the recovery of fracturedbones which injured joints, ligaments, and tendons.

These involve bone graft, growth factors, stem cells,platelet-infused plasma, autologous blood, and autologous controlled serum. Themesenchymal stem cells (MSCs) contained in the bone marrow has been shown to besuccessful in the production of the appropriate tissues.

Result in Orthopedic Procedures

Recent advances in this area, including growth factor andstem cell therapies, may contribute to faster recovery. One breakthrough isdrug-free bone grafts, which may be used to cure conditions such as orthopedicsurgery. Clinical trials have demonstrated that growth factors can improve thehealing cycle.

Stem cells will continually self-regenerate and transforminto either form of cell, providing an unmatched source of regenerativemedicine technology. Definitions of musculoskeletal procedures utilizing stemcells are listed below.

Biotechnology firms began utilizing orthopedic stemcells. For starters, BioTime works on stem cell therapies for age-relateddegenerative diseases, IntelliCell BioSciences on adipose-derived stem cellsfor orthopedic conditions, and Bio-Tissues on Ortho-biological treatments forcartilage defects.

Orthopedic procedures using robots are less intrusive anddeliver reproducible accuracy, resulting in shorter hospital stays and quickerrecovery times. The Swiss clinic, La Source, recorded a decline in averagehospitalization from 10 to 6 days with the usage of surgical robots.Nevertheless, this technology is also costly to develop, so solid,evidence-based trials are required to prove that robotic technology contributesto improved outcomes.

The Da Vinci Surgical Method became the first U.S. Food andDrug Administration (FDA)-an authorized robotic surgery program in 2000. Morebusinesses are investing in this technology to enhance navigation duringservice or to receive 3-D scans that aid in the design of custom joints.

Organizations that are interested, in robotics areinclined towards the following technological masterpieces:

Several modern surgical techniques are enhancing theresults. These involve motion-preservation methods, minimally intrusive surgery,tissue-guided surgery, and cement-free joint repair.

Motion recovery strategies require partial or completedisk removal and the usage of active stability systems and interspinous spacersthat do not impair versatility.

Minimally intrusive procedures involve the use ofendoscopes, tubular retractors, and computer-aided guidance devices, allowingan incision of just 2 cm instead of 12 cm in conventional therapies. Minimallyinvasive treatments are gaining popularity in joint and hip replacement and spinalsurgery.

Smart devices provide built-in sensors to offer real-timetracking and post-operative evaluation details to surgeons for better patientsafety across the clinical process. Such implants have the ability to minimizeperiprosthetic infection, which is an increasing orthopedic issue.Sensor-enabled innovations also presented health care professionals with arange of innovative, cost-effective goods.

Companies working in this field include:

3-D orthopedic printing is gaining traction in themanufacture of personalized braces, surgical equipment, and orthotics from arange of materials. 3-D printing technology cuts operating times, saves energy,increases the long-term reliability of the implant, and enhances the healtheffects of surgical procedures. 3-D printing technologies of orthopedics areinclusive of:

Companies investing in 3-D Orthopedic Printing

Medical science has taken a huge turn with the introduction of technology. The orthopedic industry has also transformed to a huge extent making sure that the specialists and surgeons are able to treat and operate on their patients without any hassle. Almost all the orthopedic hospitals are equipped with high-end gadgets and tools to assist the doctor.

Even though the technology has evolved greatly since thefield of medicine was invented, it is important to understand that this is justa beginning and there are many more things to come in the future.

View original post here:
The Latest Technological Innovations in Orthopedic Surgery 2020 Technology - IMC Grupo

Recommendation and review posted by Bethany Smith

The targeted drug Qinlock, which interferes with the activity of proteins that drive gastrointestinal stromal tumor, has been approved by the Food and Drug Administration for patients with advanced disease that has progressed despite treatment with other kinase inhibitors.

The targeted drug, a kinase inhibitor that interferes with the activity of the cancer-driving proteins KIT and PDGFR, is for adults with GIST who have received prior treatment with three or more kinase inhibitors, including Gleevec (imatinib).

The approval is based on findings from the phase 3 INVICTUS trial, in which the drug led to an 85% reduction in the risk of disease progression or death compared with placebo for the target population.

"Despite the progress that has been made over the past 20 years in developing treatments for GIST, including four FDA-approved targeted therapies imatinib in 2002, sunitinib in 2006, regorafenib in 2013 and avapritinib earlier this year some patients don't respond to treatment and their tumors continues to progress. Today's approval provides a new treatment option for patients who have exhausted all FDA-approved therapies for GIST," Dr. Richard Pazdur, director of the FDA's Oncology Center of Excellence and acting director of the Office of Oncologic Diseases in the FDA's Center for Drug Evaluation and Research, stated in a press release.

Results showed that the median time until disease progression was 6.3 months with Qinlock compared with 1 month for placebo. At six months, 51% of those on the novel targeted therapy had experienced no disease progression, compared with 3.2% of those taking placebo.

Additionally, there was a 64% reduction in the risk of death with Qinlock compared with placebo. The median overall survival (the length of life from the start of study treatment) was 15.1 versus 6.6 months for Qinlock and placebo, respectively, although that findings statistical significance was not conclusively established. The six-month overall survival rate with Qinlock was 84.3% compared with 55.9% for placebo. The 12-month overall survival rate was 65.4% for Qinlock compared with 25.9% for placebo.

Finally, the objective response rate (the proportion of patients who had a complete or partial response to treatment) with Qinlock was 9.4% compared with no responses in the placebo group. These findings were not statistically significant. The median duration of response had not yet been reached, with seven of eight patients continuing to respond at the time of the data cutoff of May 31, 2019.

Side effects were experienced by 98.8% of patients in the Qinlock arm compared with 97.7% with placebo. Serious or severe side effects that emerged during treatment were experienced by 49.4% of patients in the Qinlock group compared with 44.2% of those taking placebo.

The most common side effects in the Qinlock and placebo groups, respectively, were hair loss (51.8% versus 4.7%), fatigue (42.4% versus 23.3%), nausea (38.8% versus 11.6%), abdominal pain (36.5% versus 30.2%), constipation (34.1% versus 18.6%) and muscle pain (31.8% versis 11.6%). The most common serious or severe grade side effects in the Qinlock versus placebo groups were, respectively, anemia (9.4% versus 14%), high blood pressure (7.1% versus 0%) and abdominal pain (7.1% versus 4.7%).

Check back later for what you need to know about this approval.

Go here to see the original:
FDA Approves Qinlock for Patients with Pretreated, Advanced GIST - Curetoday.com

Recommendation and review posted by Bethany Smith

VANCOUVER, Washington, May 15, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (CytoDyn or the Company), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced it is offering comprehensive cytokine profiling (including RANTES levels) through its diagnostic partner company, IncellDx, to help physicians understand the pathogenesis of Childhood Inflammatory Disease Related to COVID-19. These laboratory tests are exploratory in nature and not intended for clinical decision making.

Recent reports in parts of the U.S. and Europe suggest a rare and potentially fatal inflammatory disease linked to the novel coronavirus is afflicting a small number of children. The condition resembles a rare childhood illness called Kawasaki disease, which has similar signs and symptoms and can lead to enlargement of blood vessels that in severe forms may cause heart damage.

New York State Department of Health is investigating 110 reported cases and 3 deaths in children - predominantly school-aged - experiencing symptoms similar to Kawasaki disease and toxic shock-like syndrome, possibly due to COVID-19.

Bruce Patterson, M.D., Chief Executive Officer and founder of IncellDx, a diagnostic partner and an advisor to CytoDyn commented, Cytokines are proteins that modulate the inflammatory response. Kawasaki disease has been previously shown to be associated with elevated levels of RANTES, a protein we have shown to be significantly elevated in mild-moderate COVID-19 and over 100 times normal in critical COVID-19 patients.

Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn added, We hope our comprehensive cytokine testing will help physicians gain a better understanding of the disease process and, in turn, explore the prospect for leronlimab to potentially provide a therapeutic benefit to children suffering from inflammatory illness related to COVID-19.

About Coronavirus Disease 2019CytoDyn is currently enrolling patients in two clinical trials for COVID-19, a Phase 2 randomized clinical trial for mild-to-moderate COVID-19 population in the U.S. and a Phase 2b/3 randomized clinical trial for severe and critically ill COVID-19 population in several hospitals throughout the country.

SARS-CoV-2 was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China. The origin of SARS-CoV-2 causing the COVID-19 disease is uncertain, and the virus is highly contagious. COVID-19 typically transmits person to person through respiratory droplets, commonly resulting from coughing, sneezing, and close personal contact. Coronaviruses are a large family of viruses, some causing illness in people and others that circulate among animals. For confirmed COVID-19 infections, symptoms have included fever, cough, and shortness of breath. The symptoms of COVID-19 may appear in as few as two days or as long as 14 days after exposure. Clinical manifestations in patients have ranged from non-existent to severe and fatal. At this time, there are minimal treatment options for COVID-19.

About Leronlimab (PRO 140) and BLA Submission for the HIV Combination Therapy The FDA has granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for deadly diseases. The first as a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer. Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases, including NASH. Leronlimab has completed nine clinical trials in over 800 people, including meeting its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients).

In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab could significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use.

The Company filed its BLA for Leronlimab as a Combination Therapy for Highly Treatment Experienced HIV Patients with the FDA on April 27, 2020, and submitted additional FDA requested clinical datasets on May 11, 2020. After the BLA submission is deemed completed, the FDA sets a PDUFA goal date. CytoDyn has Fast Track designation for leronlimab and a rolling review for its BLA, as previously assigned by the FDA, and the Company plans to request a priority review for the BLA. A priority review designation means the FDAs goal is to take action on the marketing application within six months of receipt (compared with 10 months under standard review).

In the setting of cancer, research has shown that CCR5 may play a role in tumor invasion, metastases, and tumor microenvironment control. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown that blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by more than 98% in a murine xenograft model. CytoDyn is, therefore, conducting a Phase 1b/2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation in May 2019.

The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation. It may be crucial in the development of acute graft-versus-host disease (GvHD) and other inflammatory conditions. Clinical studies by others further support the concept that blocking CCR5 using a chemical inhibitor can reduce the clinical impact of acute GvHD without significantly affecting the engraftment of transplanted bone marrow stem cells. CytoDyn is currently conducting a Phase 2 clinical study with leronlimab to support further the concept that the CCR5 receptor on engrafted cells is critical for the development of acute GvHD, blocking the CCR5 receptor from recognizing specific immune signaling molecules is a viable approach to mitigating acute GvHD. The FDA has granted orphan drug designation to leronlimab for the prevention of GvHD.

About CytoDyn CytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a critical role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and immune-mediated illnesses, such as GvHD and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients. CytoDyn filed its BLA in April 2020 to seek FDA approval for leronlimab as a combination therapy for highly treatment experienced HIV patients, and submitted additional FDA requested clinical datasets on May 11, 2020. CytoDyn is also conducting a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. CytoDyn plans to initiate a registration-directed study of leronlimab monotherapy indication. If successful, it could support a label extension. Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV. No drug-related serious site injection reactions reported in about 800 patients treated with leronlimab and no drug-related SAEs reported in patients treated with 700 mg dose of leronlimab. Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than five years. CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. More information is at http://www.cytodyn.com.

Forward-Looking Statements This press release contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as believes, hopes, intends, estimates, expects, projects, plans, anticipates and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Forward-looking statements specifically include statements about leronlimab, its ability to have positive health outcomes, the possible results of clinical trials, studies or other programs or ability to continue those programs, the ability to obtain regulatory approval for commercial sales, and the market for actual commercial sales. The Companys forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks and uncertainties including: (i) the sufficiency of the Companys cash position, (ii) the Companys ability to raise additional capital to fund its operations, (iii) the Companys ability to meet its debt obligations, if any, (iv) the Companys ability to enter into partnership or licensing arrangements with third parties, (v) the Companys ability to identify patients to enroll in its clinical trials in a timely fashion, (vi) the Companys ability to achieve approval of a marketable product, (vii) the design, implementation and conduct of the Companys clinical trials, (viii) the results of the Companys clinical trials, including the possibility of unfavorable clinical trial results, (ix) the market for, and marketability of, any product that is approved, (x) the existence or development of vaccines, drugs, or other treatments that are viewed by medical professionals or patients as superior to the Companys products, (xi) regulatory initiatives, compliance with governmental regulations and the regulatory approval process, (xii) general economic and business conditions, (xiii) changes in foreign, political, and social conditions, and (xiv) various other matters, many of which are beyond the Companys control. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the Securities and Exchange Commission. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this press release.

CYTODYN CONTACTSInvestors: Dave Gentry, CEO RedChip Companies Office: 1.800.RED.CHIP (733.2447) Cell: 407.491.4498 dave@redchip.com

Follow this link:
CytoDyn to Offer No-Cost Exploratory Laboratory Testing for Childhood Inflammatory Disease Associated with COVID-19 - The Bakersfield Californian

Recommendation and review posted by Bethany Smith

The danger of cancer continues to cast a shadow of fear in the lives of Indian women. According to experts, the women being diagnosed grow younger by day compared to the same in developed countries. UK-born Dr Asima Mukhopadhyay is a clinician-scientist in womens cancer. Having set up the Project Ovarian Transnational Group of Studies in Kolkata in 2015 and the Kolkata Gynecological Oncology Trials and Translational Research Group, the first-ever research group from India to become a member of the Gynecological Cancer Intergroup, she is one of the leading voices in women's cancer research and in the country. This year, she donated her royalty money as a co-developer of the PARP inhibitor Rucaparib (an anti-cancer drug) to build research capacity for cancer in India. We spoke to her about what needs to be done in cancer research in the country and how we can ensure that treatment reaches the people who need it the most. Excerpts:

What is the current status of women's cancer care in India? Could you outline the areas where we need to move ahead?

The keys areas where we need to move ahead are public awareness through media and community-based programmes. School and college health education would be a major step in ensuring that women with symptoms get to see a cancer specialist in regional cancer centres in the first place rather than reaching thereafter a significant financial drain and loss in valuable time or inadequate treatment. Secondly, we need more trained specialists and dedicated organ-specific cancer teams capable of addressing our specific needs. We also need preventive measures like vaccination, screening, genetic testing and risk-reducing surgeries, as well as ensuring access to life-saving cancer drugs and treatment options.

What led you to make the decision to donate your royalty payment?

On a personal front, I decided on a career in cancer care and research after the demise of my father at a relatively young age in 1998 due to cancer. It was not so long after that I had graduated from Medical College Kolkata. As a cancer survivor family and a young budding doctor, I had the first-hand experience of the emotional, social and economic turmoil and helplessness that one has to undergo to fight this disease and the need for better treatment options and research towards this.

After my return to India in 2015 from the UK, I had joineda reputed cancer centre in Kolkata as an onco-surgeon; I noticed that in India, a majority of cancer patients are not aware of the need to participate in studies or clinical trials which automatically improves the quality of care. In countries like the UK, major cancer research organisations are heavily supported through public funding and donations. We need similar support mechanisms in India including media support and goodwill for promoting better patient care.

Could you describe your discovery around epithelial ovarian cancer and the implications it has for treating cancer?

It had been previously shown by the Newcastle University group of researchers in the UK and various other groups that cancers harbouring a genetic defect in the BRCA genes are very sensitive to a new class of anti-cancer drug called PARP inhibitors. I joined this group in 2008 as a clinician-researcher for my PhD. In 2010, I showed that approximately that 50% epithelial ovarian cancer patients harbour a defect called BRCAness or homologous recombination deficiency (HRD), therefore providing the scope for extending the use for PARP inhibitors to a lot more women compared to only 10-20% of women who have inherited detects in the BRCA gene.

In 2011, this was published as the first-ever report showing the importance of functional BRCAness. I developed a functional biomarker assay (used to understand the mechanism of action of a drug) using ascitic fluid from ovarian cancer patients at the Northern Gynaecological Oncology Centre in Gateshead. After 10 years of my original publication, there is a renewed interest in adopting the functional HRD assay as a better biomarker for selecting patients suitable for PARP inhibitor therapy.

Are women in India at a position where they can seek medical help successfully? How do we spread more gynaecological awareness among the general public?

Partially, yes. There are health systems available and women can seek proper medical health at the tertiary centres. However, many primary and secondary health centres are not much developed and we often find patients referred to us with partial or incomplete treatment. The need of the hour is to train the trainer. Healthcare workers should be trained regarding various cancers, their symptoms, risk factors, hereditary factors and their preventive and treatment opportunities, so that they are able to identify the population at risk of cancers and create health education camps for enlightening the population.

School health awareness campaigns can be created so that children of ages 12 years and above are educated regarding breast self-examination, menstrual hygiene, personal hygiene, obesity and hereditary cancer history so that they are aware of their physical and hereditary risks and act accordingly to prevent cancers in future. These children are the future of our society and if we can incorporate the knowledge of health awareness, the cancer risk in women will sufficiently decrease in future. I firmly believe that if we can incorporate such community-based awareness and screening camps integrated within the existing governmental structures, the access of women from low-income households will surely increase.

See more here:
Meet this Newcastle University scientist who donated all her royalty money to improve cancer research in India - EdexLive

Recommendation and review posted by Bethany Smith

Trying to hack fitness is a multi-million-dollar industry; weve all seen at least one ad featuring a purported miracle product that claims it can make people lose weight and look greatwithout even trying. From low-effort exercise machines to strange-ingredient diets to fat-burning belts and bands, theres no shortage of attempts to make it easy to be fit.

A gene therapy trial performed on mice may foreshadow yet another way to hack fitness. In a study done by a team at Washington University in St. Louis medical school, mice quickly built muscle mass and reduced obesity after receiving the therapy, even while eating a diet high in fat and not exercising. The results were published last week in a paper in Science Advances.

Sound appealing? Heres how it worked.

The gene targeted was FST, which is responsible for making a protein called follistatin. In humans and most other mammals, follistatin helps grow muscle and control metabolism by blocking a protein called myostatin, which acts to restrain muscle growth and ensure muscles dont get too big.

The researchers injected eight-week-old mice with a virus carrying a healthy FST gene (gene therapy involves adding healthy copies of a gene to cells, usually using a virus as a deliveryman).

Over a period of 18 weeks, or about 4 months, the team observed that the muscle mass of the treated mice more than doubled, as did their strength level. They also experienced reduced damage related to osteoarthritis, less inflammation in their joints, and had healthier hearts and blood vessels than mice that didnt receive the gene therapyeven though all the mice ate the same high-fat diet and did the same amount of exercise.

Going into the study, the researchers worried the muscle growth catalyzed by the gene therapy could harm the heart, mainly through thickening of the hearts walls. Surprisingly, though, heart function and cardiovascular health of the treated mice actually improved. In subsequent studies, the team will continue to monitor the treatments effect on the heart, as complications could emerge over time.

Talk about a fitness hack; imagine being able to build muscle and maintain a healthy metabolism while lounging on the couch eating burgers and fries. There have been similar studies to replicate the effects of exercise by commandeering the genetic instructions that control the way cells interact with proteins; though various exercise pills have successfully mimicked the effects of regular cardiovascular activity in mice, scientists still dont fully understand how, at a molecular level, exercise has the effects it does on the human body.

This may change in the next couple years, though; a National Institutes of Health consortium called the Molecular Transducers of Physical Activity is in the midst of an in-depth study on the molecular effects of exercise on tissues and organs in 3,000 people.

If the muscle-building gene therapy eventually reaches a point where it can be used in humans, though, the research team isnt viewing it as a quick-fix health hack. Rather, it would be used to help get people with conditions like muscular dystrophy or severe obesity to a baseline from which they could adopt tried-and-true muscle-building practices like weight lifting or physical therapy.

In cases of severe obesity or muscle loss, it is extremely difficultif not impossibleto lose weight or improve muscle strength through normal exercise and diet, said Farshid Guilak, orthopedic surgery professor and director of research at Shriners Hospitals for Children in St. Louis. The goal of this study was to show the importance of muscle strength in overriding many of the harmful effects of obesity on the joint.

If every condition, process, and trait in our bodies is tightly linked to our genes, its conceivable that almost any aspect of our health could be manipulated using gene therapy and related tools. Maybe one day there will indeed be a pill we can take or a shot we can get to give us svelte, muscular bodies without any of the effort.

The fact that this would ruin the pleasure and satisfaction of a good workout is another conversationand one not everybody would be interested in having. But even if genetic or chemical exercise-replacement tools become safe to use in humans in the foreseeable future, theyll likely be limited, at least at first, to those who need them due to debilitating health conditions.

That saidfor the time being, keep hitting the treadmill, the weight room, or your other off-the-couch, effort-intensive workout of choice.

Image Credit: Aberro Creative from Pixabay

See the article here:
Forget ExerciseThese Mice Got Ripped With Gene Therapy - Singularity Hub

Recommendation and review posted by Bethany Smith

In 2019, the Philadelphia region was home to just under 5,000 cell and gene therapy jobs. But in 2029, we could be looking at more than doubling that figure, a report commissioned by three regional economic and research groups found recently.

The Chamber of Commerce for Greater Philadelphiasregional CEO Council for Growth, the University City Science Center, and University City Districts West Philadelphia Skills Initiative banded together with support from the Lenfest Foundation to take a closer look at the state of jobs in cell and gene therapy, along with the industrys future.

The project, titled the Cell and Gene Therapy and Connected Health Workforce Analysis, found that cell and gene therapy jobs will likely grow between 35% to 94% in the next 10 years with mid-range growth estimates and as much as 54% to 136% with high-range growth estimates.

So, a decade from now, we could see anywhere between the low-end projection of 7,608 jobs and the high-range projection of 11,274 jobs.

Surveys, interviews and focus groups with academic researchers, industry and human resources experts, and workforce development organizations informed the report, and helped develop potential scenarios, the Science Center said in a release.

The objective of the study was to characterize the current landscape, assess growth scenarios and project future talent needs for these two particularly dynamic industry subsectors, said Saul Behar, the Science Centers SVP for advancement and strategic initiatives.

The findings confirm that the region is on track to become a leader in the space, and that Philly is positioned to recruit and train thousands of new employees over the next few years, Behar said.

Those jobs will likely pull from the wealth of pharma companies in the region, but will still require some extra training, the report said. Roles like manufacturing technicians, particularly within contract manufacturing organizations, might rise in demand as tech innovations allow for growth in therapy manufacturing.

And as cell and gene therapy firms grow, there will be opportunities for a diverse workforce from multiple education and skill levels, and firms will also require workers with backgrounds in finance, information technology, legal services, human resources and general operations.

(Ensuring that jobs in the biotech and cell and gene therapy space are not just for highly educated folks has been the focus of recent efforts of a handful of organizations across the city, including the West Philadelphia Skills Initiative; find a deeper dive into that initiative here.)

And to attract talented workers, startups must be able to explain their distinct value proposition offered by working in an emerging, fast-growing industry, the report said.

The study was conducted before the coronavirus pandemic began in the region, but those collaborating on the study think that it will actually help spur innovation in the region.

The search for new cures, therapies and treatments, as well as the role of data analytics, and the importance of connected health are top of mind and will continue to be a core strength of and competitive advantage for our region, said Claire Marrazzo Greenwood, executive director of CEO Council for Growth.

View post:
Study: The Philly region is on track to add thousands more cell and gene therapy jobs in the next 10 years - Technical.ly

Recommendation and review posted by Bethany Smith

A recent market intelligence study on the Gene Therapy market2020incorporates proprietary techniques and assessment tools to screen the Gene Therapy market for the forecast period, 2020-2026. Additionally, valuable insights pertaining to the market size, share and growth rate of Gene Therapy market offers a greater chance of success for all business owners, products, and new technology.

Major Gene Therapy market players covered by this research report are:

Sibiono GeneTech,Advantagene,Spark Therapeutics,Shanghai Sunway Biotech Co. LtdBluebird Bio,UniQure NVAvalanche Bio,Celladon,Sangamo,Dimension Therapeutics

Request for Sample Report @ https://www.reportspedia.com/report/life-sciences/global-gene-therapy-market-research-report-2014-2026-of-major-types,-applications-and-competitive-vendors-in-top-regions-and-countries/44997 #request_sample

Incorporated with Info-graphics, charts, tables and figures, this research report Gene Therapy Market Size, Type Analysis, Application Analysis, End-Use Industry Analysis, Regional Outlook, Competitive Strategies And Forecasts, 2020- 2026is based on a wide-ranging research of the entire Global market and covering all its sub-segments through comprehensively thorough classifications. Insightful analysis and valuation are created from superior primary and secondary information sources with data and information derived from industry specialists across the value chain. The report provides historical market data for 2015-2019, base year estimates for 2020, and forecasts from 2020 to 2026.

Research Methodology:

The research report provides trustworthy primary and secondary research. It also depends on the most recent analysis techniques to organize extremely detailed and accurate research studies such as this Gene Therapy Market. It uses data triangulation, top-down and bottom-up approaches, and advanced Gene Therapy Market research processes to come out with comprehensive and industry-best market research reports.

Classification by Type is as follows:

Viral vectorNon-viral vector

Classification by Application is as follows:

Oncological DisordersRare DiseasesCardiovascular DiseasesNeurological DisordersInfectious diseaseOther Diseases

Inquire Here For More Details Or Custom Content @ https://www.reportspedia.com/report/life-sciences/global-gene-therapy-market-research-report-2014-2026-of-major-types,-applications-and-competitive-vendors-in-top-regions-and-countries/44997 #inquiry_before_buying

Gene Therapy Market 2020 Dynamics:

Drivers:(Developing regions and growing markets)

Boundaries:(Regional, Key Player facing Issues, Future Barriers for growth)

Opportunities:(Regional, Growth Rate, Competitive, Consumption)

Regional Segmentation:

TOC of Gene Therapy Market 2020 Report Includes:

View Report TOC In detail @ https://www.reportspedia.com/report/life-sciences/global-gene-therapy-market-research-report-2014-2026-of-major-types,-applications-and-competitive-vendors-in-top-regions-and-countries/44997 #table_of_contents

Visit link:
Global Gene Therapy Market Outlook, Opportunities, Key Players, Growth, Competitive Landscape, Trends and Forecast by 2026 - Cole of Duty

Recommendation and review posted by Bethany Smith

The research study on Global Personalized Gene Therapy Treatment market 2019 presents an extensive analysis of current Personalized Gene Therapy Treatment market size, drivers, trends, opportunities, challenges, as well as key Personalized Gene Therapy Treatment market segments. Further, it explains various definitions and classification of the Personalized Gene Therapy Treatment industry, applications, and chain structure.In continuation of this data, the Personalized Gene Therapy Treatment report covers various marketing strategies followed by key players and distributors. Also explains Personalized Gene Therapy Treatment marketing channels, potential buyers and development history. The intent of global Personalized Gene Therapy Treatment research report is to depict the information to the user regarding Personalized Gene Therapy Treatment market forecast and dynamics for the upcoming years. The Personalized Gene Therapy Treatment study lists the essential elements which influence the growth of Personalized Gene Therapy Treatment industry. Long-term evaluation of the worldwide Personalized Gene Therapy Treatment market share from diverse countries and regions is roofed within the Personalized Gene Therapy Treatment report. Additionally, includes Personalized Gene Therapy Treatment type wise and application wise consumption figures.

Download Sample of This Strategic Report:https://www.kennethresearch.com/sample-request-10225585

After the basic information, the global Personalized Gene Therapy Treatment Market study sheds light on the Personalized Gene Therapy Treatment technological evolution, tie-ups, acquisition, innovative Personalized Gene Therapy Treatment business approach, new launches and Personalized Gene Therapy Treatment revenue. In addition, the Personalized Gene Therapy Treatment industry growth in distinct regions and Personalized Gene Therapy Treatment R;D status are enclosed within the report.The Personalized Gene Therapy Treatment study also incorporates new investment feasibility analysis of Personalized Gene Therapy Treatment. Together with strategically analyzing the key micro markets, the report also focuses on industry-specific drivers, restraints, opportunities, and challenges in the Personalized Gene Therapy Treatment market.

Global Personalized Gene Therapy Treatment Market Segmentation 2019: Personalized Gene Therapy TreatmentThe study also classifies the entire Personalized Gene Therapy Treatment market on basis of leading manufacturers, different types, various applications and diverse geographical regions. Overall Personalized Gene Therapy Treatment market is characterized by the existence of well-known global and regional Personalized Gene Therapy Treatment vendors. These established Personalized Gene Therapy Treatment players have huge essential resources and funds for Personalized Gene Therapy Treatment research as well as developmental activities. Also, the Personalized Gene Therapy Treatment manufacturers focusing on the development of new Personalized Gene Therapy Treatment technologies and feedstock. In fact, this will enhance the competitive scenario of the Personalized Gene Therapy Treatment industry.

The Leading Players involved in global Personalized Gene Therapy Treatment market are:

By Therapy (Targeted Treatments and Pharmacogenomics),By Application (Breast Cancer, Brain Cancer, Colorectal Cancer, Certain Childhood Cancers, Gastrointestinal Stromal Tumor, Kidney Cancer, Leukemia, Lymphoma, Melanoma, Lung Cancer, and Multiple Myeloma)By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)

Download Sample of This Strategic Report:https://www.kennethresearch.com/sample-request-10225585

Worldwide Personalized Gene Therapy Treatment Market Different Analysis:Competitors Review of Personalized Gene Therapy Treatment Market: Report presents the competitive landscape scenario seen among top Personalized Gene Therapy Treatment players, their company profile, revenue, sales, business tactics and forecast Personalized Gene Therapy Treatment industry situations. Production Review of Personalized Gene Therapy Treatment Market: It illustrates the production volume, capacity with respect to major Personalized Gene Therapy Treatment regions, application, type, and the price. Sales Margin and Revenue Accumulation Review of Personalized Gene Therapy Treatment Market: Eventually explains sales margin and revenue accumulation based on key regions, price, revenue, and Personalized Gene Therapy Treatment target consumer. Supply and Demand Review of Personalized Gene Therapy Treatment Market: Coupled with sales margin, the report depicts the supply and demand seen in major regions, among key players and for every Personalized Gene Therapy Treatment product type. Also interprets the Personalized Gene Therapy Treatment import/export scenario. Other key reviews of Personalized Gene Therapy Treatment Market: Apart from the above information, correspondingly covers the company website, number of employees, contact details of major Personalized Gene Therapy Treatment players, potential consumers and suppliers. Also, the strengths, opportunities, Personalized Gene Therapy Treatment market driving forces and market restraints are studied in this report.

Highlights of Global Personalized Gene Therapy Treatment Market Report:* This report provides in detail analysis of the Personalized Gene Therapy Treatment and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period: 2019 ; 2029. * It also elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for world Personalized Gene Therapy Treatment market. * This study also provides key insights about Personalized Gene Therapy Treatment market drivers, restraints, opportunities, new product launches, approvals, regional outlook, and competitive strategies adopted by the leading Personalized Gene Therapy Treatment players. * It profiles leading players in the worldwide Personalized Gene Therapy Treatment market based on the following parameters ; company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans. * Insights from Personalized Gene Therapy Treatment report would allow marketers and management authorities of companies to make an informed decision with respect to their future product launches, market expansion, and Personalized Gene Therapy Treatment marketing tactics. * The world Personalized Gene Therapy Treatment industry report caters to various stakeholders in Personalized Gene Therapy Treatment market. That includes investors, device manufacturers, distributors and suppliers for Personalized Gene Therapy Treatment equipment. Especially incorporates government organizations, Personalized Gene Therapy Treatment research and consulting firms, new entrants, and financial analysts. *Various strategy matrices used in analyzing the Personalized Gene Therapy Treatment market would provide stakeholders vital inputs to make strategic decisions accordingly.

Global Personalized Gene Therapy Treatment Market Report Provides Comprehensive Analysis of Following: ; Personalized Gene Therapy Treatment Market segments and sub-segments ; Industry size ; Personalized Gene Therapy Treatment shares ; Personalized Gene Therapy Treatment Market trends and dynamics ; Market Drivers and Personalized Gene Therapy Treatment Opportunities ; Supply and demand of world Personalized Gene Therapy Treatment industry ; Technological inventions in Personalized Gene Therapy Treatment trade ; Personalized Gene Therapy Treatment Marketing Channel Development Trend ; Global Personalized Gene Therapy Treatment Industry Positioning ; Pricing and Brand Strategy ; Distributors/Traders List enclosed in Positioning Personalized Gene Therapy Treatment Market.

Request For Full Report:https://www.kennethresearch.com/sample-request-10225585

Moreover, the report organizes to provide essential information on current and future Personalized Gene Therapy Treatment market movements, organizational needs and Personalized Gene Therapy Treatment industrial innovations. Additionally, the complete Personalized Gene Therapy Treatment report helps the new aspirants to inspect the forthcoming opportunities in the Personalized Gene Therapy Treatment industry. Investors will get a clear idea of the dominant Personalized Gene Therapy Treatment players and their future forecasts.

About Kenneth Research:

Kenneth Research provides market research reports to different individuals, industries, associations and organizations with an aim of helping them to take prominent decisions. Our research library comprises of more than 10,000 research reports provided by more than 15 market research publishers across different industries. Our collection of market research solutions covers both macro level as well as micro level categories with relevant and suitable market research titles. As a global market research reselling firm, Kenneth Research provides significant analysis on various markets with pure business intelligence and consulting services on different industries across the globe. In addition to that, our internal research team always keep a track on the international and domestic market for any economic changes impacting the products demand, growth and opportunities for new and existing players.

Contact Us

Kenneth ResearchEmail: [emailprotected]Phone: +1 313 462 0609

Go here to read the rest:
Personalized Gene Therapy Treatment Market Analysis By Industry Size, Share, Revenue Growth, Development And Demand Forecast To 2029 3w Market News...

Recommendation and review posted by Bethany Smith

Moncef Slaoui stepped off Modernas board of directors on Friday and pivoted straight into the high profile role heading the Trump administrations Project Warp Speed, where hell be in charge of accelerating Modernas and others vaccines to a rapid release for a pandemic weary world.

The news became official mid-day Friday after numerous reports earlier that he had been picked off the short list of candidates.

Slaouis role on Modernas board earned a compensation package valued at $490,000 last year, something consumer advocates quickly fixed on as a conflict of interest. Its unlikely that critics will be satisfied by Slaouis resignation, though Moderna has already done quite well for itself without any added help from Slaoui. The biotech has benefited extensively from major support from BARDA and the NIH and will continue to enjoy close contacts in Washington, including at the FDA.

As the lead developer in the US of a new vaccine, Moderna also offers the White House a Boston-based company that can potentially provide a US hero to resolve the pandemic. So its likely Trumps favorite player with or without Slaouis involvement.

Moderna CEO Stphane Bancel is part of a small band of vaccines execs who believes its possible to do something that would have been considered impossible at the beginning of the year: hustle a new vaccine straight through a Phase I-III program in a matter of months and come up with just enough pivotal efficacy and safety data to start distribution in the fall.

While billions of people eagerly want that, theres also been some significant pushback from a variety of experts in the field who wonder if its really feasible to be able to field a Covid-19 vaccine in less than 2 years in itself something of a miracle in a sector where development can take years and sometimes decades.

Slaouis position will have already been molded by his board post. And it will fit neatly into the administrations own view that they can make it happen. Speaking at the White House today, he mentioned seeing unpublished data presumably Modernas that suggested success is close at hand, according to Politico.

These data made me feel even more confident that we will be able to deliver a few hundred million doses of vaccine by the end of 2020, he said.

We wont have long to wait.

See the original post:
Moncef Slaoui pivots from Moderna's board to the helm of Project Warp Speed. His task: Overnight success - Endpoints News

Recommendation and review posted by Bethany Smith

LONDON--(BUSINESS WIRE)--The global mycoplasma testing market size is expected to grow by USD 445.57 million as per Technavio. This marks a significant market growth compared to the 2019 growth estimates due to the impact of the COVID-19 pandemic in the first half of 2020. Moreover, steady growth is expected to continue throughout the forecast period, and the market is expected to grow at a CAGR of over 11%.

Request for Technavio's latest reports on directly and indirectly impacted marketsMarket estimates include pre- and post-COVID-19 impact on the mycoplasma testing market -

Download free sample report

The global outbreak of COVID-19 has compelled several companies in the healthcare industry to focus on finding a cure for this life-threatening disease. The number of pharmaceutical and biotechnology companies that focus on biomedical research is increasing, resulting in rising demand for mycoplasma testing to identify and eliminate mycoplasma contamination during the development of cell-derived biological and pharmaceutical products. However, the global outbreak of coronavirus is expected to have a neutral impact on the growth of the mycoplasma testing market during the forecast period.

Technavio's custom research reports offer detailed insights on the impact of COVID-19 at an industry level, a regional level, and subsequent supply chain operations. This customized report will also help clients keep up with new product launches in direct & indirect COVID-19 related markets, upcoming vaccines and pipeline analysis, and significant developments in vendor operations and government regulations.

https://www.technavio.com/report/global-mycoplasma-testing-market-industry-analysis

The market is driven by the increasing focus on R&D of biopharmaceuticals. In addition, the growing M&A and partnerships between CROs, and pharmaceutical and biotechnology companies is anticipated to boost the growth of the mycoplasma testing market.

New class therapeutics such as cell therapy and gene therapy are gaining popularity as a novel treatment for many chronic and acute diseases. Thus, many pharmaceutical companies and research institutes are concentrating on the R&D of these products owing to their huge market potential. However, cell therapy products witness challenges around sterilization and its storage, as a result of which, it has to be immediately administered to the patients. Common mycoplasma species such as Acholeplasma laidlawii, Mycoplasma arginini, Mycoplasma bovis, Mycoplasma fermentans, and Mycoplasma salivarium have been identified as contamination in cell cultures and the biopharmaceutical processes. A product developed with mycoplasma contamination triggers serious side effects in humans. This is driving the demand for mycoplasma test kits. Rapid mycoplasma test kits are commercially available in the market that can be used in research labs and biopharmaceutical manufacturing companies for cell line qualification and in-process monitoring.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Mycoplasma Testing Companies:

Agilent Technologies Inc.

Agilent Technologies Inc. has business operations under various segments, such as life sciences and applied markets, diagnostics and genomics, and Agilent CrossLab. The company's key offerings include MycoSensor PCR Assay Kit, 50 Rxn, which is a gel-based PCR assay that can rapidly detect mycoplasma infections in the human cell lines in less than four hours.

ATCC

ATCC operates its business through various segments, such as classic media, specialty media, stem cell research, human cytogenetics, mycoplasma detection, and molecular biology. The company's key products include Universal Mycoplasma Detection Kit, which offers a quick and sensitive PCR-based test to detect mycoplasma contaminants in cell culture.

Becton, Dickinson and Co.

Becton, Dickinson and Co. has business operations under various segments, such as BD Medical, BD Life Sciences, and BD Interventional. The company's key offerings include BD MAX System, which is a fully-integrated, automated platform that performs nucleic acid extraction and real-time PCR providing results for up to 24 samples across multiple syndromes in less than three hours.

F. Hoffmann-La Roche Ltd.

F. Hoffmann-La Roche Ltd. operates its business through two segments: pharmaceuticals and diagnostics. The company's key offerings include MycoTOOL PCR Mycoplasma Detection Kit, which tests the absence of mycoplasma in cell culture samples. It supplies all reagents for the amplification step. It is an in-vitro amplification test optimized for detection of mycoplasma in cell culture.

InvivoGen

InvivoGen has business operations under various segments, such as research fields, biological tools, and custom services. The company offers PlasmoTest, which is the first assay to utilize cells to signal the presence of mycoplasma. It is a simple, rapid, and reliable assay for the visual detection of mycoplasma contamination in cell cultures.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Mycoplasma Testing Regional Outlook (Revenue, USD mn, 2020-2024)

Mycoplasma Testing End-user Outlook (Revenue, USD mn, 2020-2024)

Technavios sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Link:
Analysis on Impact of COVID19-Global Mycoplasma Testing Market 2020-2024 | Evolving Opportunities with Agilent Technologies Inc. and ATCC | Technavio...

Recommendation and review posted by Bethany Smith

The recently published market study by GLOBAL MARKETERS.BIZ highlights the current trends that are expected to influence the dynamics of the Gene Therapy market in the upcoming years. The report introspect the supply chain, cost structure, and recent developments pertaining to the Gene Therapy market in the report and the impact of the COVID-19 on these facets of the market. Further, the micro and macro-economic factors that are likely to impact the growth of the Gene Therapy market are thoroughly studied in the presented market study.

Get PDF Samplecopy(including TOC, Tables, and Figures) @https://www.globalmarketers.biz/report/automotive-and-transportation/global-automotive-gasoline-engine-turbocharger-market-2019-by-manufacturers,-regions,-type-and-application,-forecast-to-2024/130925#request_sample

Leading Players Are :

Bluebird BioSangamoSpark TherapeuticsDimension TherapeuticsAvalanche BioCelladonVical Inc.Advantagene

Reasons to Trust Our Business Insights

Proven track record of delivering high-quality and insightful market studies

Data collected from credible sources including product managers, sales representatives, marketing executives, and more

Providing accurate insights for over ten industrial verticals

Swift delivery of reports with COVID-19 impact without any delays

Up-to-date market research and analytical tools used to curate market reports

Critical Data in the Gene Therapy Market Report

Company share analysis and competition landscape

Recent trends and notable developments in the Gene Therapy market space

Growth projections of each market segment and sub-segment during the forecast period

COVID-19 impact on the global Gene Therapy market

Recent innovations, product launches, and technological advances relevant to the Gene Therapy market

Regional Assessment

The regional assessment chapter in the report offers an out and out understanding of the potential growth of the Gene Therapy market across various geographies such as:

Application Assessment

The presented study ponders over the numerous applications of the Gene Therapy and offers a fair assessment of the supply-demand ratio of each application including:

Market Taxonomy

By Type

Ex vivoIn Vivo

By Application

CancerMonogenicInfectious diseaseCardiovascular diseaseOther

Enquire Here For Customization:

https://www.globalmarketers.biz/inquiry/customization/130925

By Region

North America

Latin America

Europe

China

Japan

SEA and Other APAC

MEA

Get Table of Contents with Charts, Figures & Tables https://www.globalmarketers.biz/report/automotive-and-transportation/global-automotive-gasoline-engine-turbocharger-market-2019-by-manufacturers,-regions,-type-and-application,-forecast-to-2024/130925#table_of_contents

The report resolves the following doubts related to the Gene Therapy market:

1. Who are the leading market players operating in the current Gene Therapy market landscape?

2. Which region is expected to dominate the Gene Therapy market in terms of market share and size during the forecast period?

3. What are the various factors that are likely to contribute to the growth of the Gene Therapy market in the upcoming years?

4. What is the most impactful marketing strategy adopted by players in the Gene Therapy market?

5. What is the projected CAGR growth of application 1 during the forecast period?

See more here:
Global Gene Therapy Market By Manufacturers, Types, Regions and Application and Forecast to 2025 - Cole of Duty

Recommendation and review posted by Bethany Smith